

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)Date of mailing (day month year)
12 March 2001 (12.03.01)

From the INTERNATIONAL BUREAU

To:

VIEILLEFOSSE, Jean-Claude
Aventis Pharma S.A.
102, route de Noisy
F-93235 Romainville Cedex
FRANCEApplicant's or agent's file reference
HMR99L036PCT

IMPORTANT NOTIFICATION

International application No.
PCT/EP00/05920International filing date (day month year)
26 June 2000 (26.06.00)

1. The following indications appeared on record concerning:

 the applicant the inventor the agent the common representative

Name and Address

VIEILLEFOSSE, Jean-Claude
Hoechst Marion Roussel
102, route de Noisy
F-93235 Romainville Cedex
France

State of Nationality

State of Residence

Telephone No.

01 49 91 57 27

Facsimile No.

01 49 91 46 10

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

 the person the name the address the nationality the residence

Name and Address

VIEILLEFOSSE, Jean-Claude
Aventis Pharma S.A.
102, route de Noisy
F-93235 Romainville Cedex
France

State of Nationality

State of Residence

Telephone No.

01 49 91 57 27

Facsimile No.

01 49 91 46 10

Teleprinter No.

3. Further observations, if necessary:

The indication of a new company's name of the agent on the Demand (Form PCT/IPEA/401) has
been considered a request for recording a change under Rule 92bis. In case of

4. A copy of this notification has been sent to:

 the receiving Office the designated Offices concerned the International Searching Authority the elected Offices concerned the International Preliminary Examining Authority other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Claudio Borton

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TRF^TY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

| |
|----------------------------------|
| Date of mailing (day month year) |
| 12 March 2001 (12.03.01) |

| | |
|----|---|
| To | Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 ETATS-UNIS D'AMERIQUE |
| | in its capacity as elected Office |

| | |
|--|---------------------------------------|
| International application No. | Applicant's or agent's file reference |
| PCT/EP00/05920 | HMR99L036PCT |
| International filing date (day/month/year) | Priority date (day/month/year) |
| 26 June 2000 (26.06.00) | 02 July 1999 (02.07.99) |
| Applicant | |
| PEYMAN, Anuschirvan et al | |

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

20 January 2001 (20.01.01)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

| | |
|---|--|
| The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35 | Authorized officer Claudio Borton Telephone No.: (41-22) 338.83.38 |
|---|--|

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

VIEILLEFOSSE, Jean-Claude
AVENTIS PHARMA S.A.
102, route de Noisy
F-93235 Romainville Cedex
FRANCE

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

| | | | |
|--|---|---|------------|
| | | Date of mailing (day/month/year) | 10.09.2001 |
| Applicant's or agent's file reference HMR99L036PCT | | IMPORTANT NOTIFICATION | |
| International application No. PCT/EP00/05920 | International filing date (day/month/year) 26/06/2000 | Priority date (day/month/year) 02/07/1999 | |
| Applicant AVENTIS PHARMA DEUTCHLAND GMBH et al. | | | |

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Hebert, W

Tel. +49 89 2399-2152



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| | | | |
|--|--|--|---|
| Applicant's or agent's file reference HMR99L036PCT | FOR FURTHER ACTION | | See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) |
| International application No. PCT/EP00/05920 | International filing date (day/month/year) 26/06/2000 | Priority date (day/month/year) 02/07/1999 | |
| International Patent Classification (IPC) or national classification and IPC C07D473/34 | | | |
| Applicant AVENTIS PHARMA DEUTCHLAND GMBH et al. | | | |

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

| | |
|---|--|
| Date of submission of the demand 20/01/2001 | Date of completion of this report 10.09.2001 |
| Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 | Authorized officer Papathoma, S Telephone No. +49 89 2399 7536 |



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/05920

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):
Description, pages:

1-54 as originally filed

Claims, No.:

1-10 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
 - the language of publication of the international application (under Rule 48.3(b)).
 - the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
- contained in the international application in written form.
 - filed together with the international application in computer readable form.
 - furnished subsequently to this Authority in written form.
 - furnished subsequently to this Authority in computer readable form.
 - The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4. The amendments have resulted in the cancellation of:
- the description, pages:
 - the claims, Nos.:
 - the drawings, sheets:
5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/05920

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

| | |
|---------------------|-----------------------|
| Novelty (N) | Yes: Claims 1-10 |
| | No: Claims |
| Inventive step (IS) | Yes: Claims 1-10 |
| | No: Claims |

| | |
|-------------------------------|-----------------------|
| Industrial applicability (IA) | Yes: Claims 1-10 |
| | No: Claims |

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/05920

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1: EP-A-0 853 084 (HOECHST AG ;GENENTECH INC (US)) 15 July 1998 (1998-07-15) cited in the application
- D2: WO 98 31359 A (DUGGAN MARK E ;MERCK & CO INC (US)) 23 July 1998 (1998-07-23)
- D3: WO 98 18461 A (HOFFMAN WILLIAM F ;DUGGAN MARK E (US); IHLE NATHAN C (US); MERCK &) 7 May 1998 (1998-05-07) cited in the application
- D4: WO 95 32710 A (MERCK & CO INC ;HARTMAN GEORGE D (US); DUGGAN MARK E (US); IHLE NA) 7 December 1995 (1995-12-07) cited in the application
- D5: WO 98 08840 A (HOFFMAN WILLIAM F ;HUTCHINSON JOHN H (US); MEISSNER ROBERT S (US);) 5 March 1998 (1998-03-05) cited in the application
- D6: WO 99 32457 A (CUTHBERTSON ROBERT ANDREW ;KNOLLE JOCHEN (DE); BREIPOHL GERHARD (D) 1 July 1999 (1999-07-01) cited in the application

The application refers to naphthyridine derivatives, to a process for their preparation, to their use and to pharmaceutical compositions containing them.

These naphthyridine derivatives are vitronectin receptor antagonists and inhibitors of cell adhesion. Therefore they are suitable for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature.

In particular, these derivatives are characterised by three parts:

- a) a 5,6,7,8-tetrahydro-[1,8]naphthyridine moiety
- b) a 6-(piperidin-1-yl)-purin moiety and
- c) a substituted propionic acid moiety bound to the 9-position of the purin ring.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/05920

a) Article 33(2) PCT

The prior art documents disclose also compounds, which are vitronectin receptor antagonists.

However these compounds do not contain all the three parts mentioned above. In document D1 the compounds described contain only parts b) and c), while in documents D2, D3 and D4 they contain the parts a) and c) (the compounds of document D5 contain only part a) and those of D6 only part c)).

Because of the structural differences of the compounds of the application with the ones of the prior art documents, the first are considered as novel.

Since the compounds of the application are novel, the process for their preparation, their uses and their pharmaceutical compositions are also novel and so claims 1-10 according to the Article 33(2) PCT.

b) Article 33(3) PCT

Moreover their structural differences are that wide, that a person skilled in the art would not come up to the thought of combining document D1 with one of the documents D2, D3 or D4, and therefore the compounds of the application are considered also as inventive.

Since the compounds of the application are inventive, the process for their preparation, their uses and their pharmaceutical compositions are also inventive and so claims 1-10 according to the Article 33(3) PCT.

Re Item VI

Certain documents cited

Document D7:

D7: WO 99 37621 A (CUTHBERTSON ROBERT ANDREW ;SCHEUNEMANN KARLHEINZ (DE); KNOLLE JOCH) 29 July 1999 (1999-07-29)

can not be considered as prior art document according to the Article 33(2) PCT, because it is published after the priority day and before the filing day of the application. However care should be taken by the applicant while entering the regional phase, because this document could be relevant for the examination, as it refers also to vitronectin receptor

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/05920

antagonists containing similar structural characteristics with the ones of the compounds of the application.

Re Item VII

Certain defects in the international application

Document D2 is an important document of the prior art and should be enclosed in the references the applicant makes of the background art (Rule 5.1(a)(ii) PCT).

Re Item VIII

Certain observations on the international application

Problems of unclarity occur with the substituent G:

for example problems occur with the values of n, m, i, q, A, R¹, R² and R⁴ when G is CH₂-CH(COOH)NHCOOPh; in this case

if R¹ is H, R²NHCOOAr (R⁷NHCOOR⁶), R⁴ COOH (COR⁸), m is 1 and n, i, and q is 0, then A should be -CH₂- , which is not embraced by the definition of A.

In claim 3 the definition of R³ and in claims 4, 5 and 6 the definition of R³ and R⁵ are superfluous.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02398 A1(51) International Patent Classification: **C07D 473/34,**
A61K 31/52[FR/FR]; 12, rue de la Biberonne, F-77410 Claye Souilly (FR). **RUXER, Jean-Marie** [FR/FR]; 12, Esplanade de la Manufacture, F-92130 Issy les Moulineaux (FR).

(21) International Application Number: PCT/EP00/05920

(74) Agent: **VIEILLEFOSSE, Jean-Claude**; Hoechst Marion Roussel, 102, route de Noisy, F-93235 Romainville Cedex (FR).

(22) International Filing Date: 26 June 2000 (26.06.2000)

(81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

With international search report.

(30) Priority Data:
99112636.8 2 July 1999 (02.07.1999) EP

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(71) Applicants (for all designated States except US): **AVENTIS PHARMA DEUTSCHLAND GMBH** [DE/DE]; Brüningstrasse 50, D-65929 Frankfurt am Main (DE).

GENENTECH INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PEYMAN, Anuschiryan** [DE/DE]; Zeilsheimer Strasse 46, D-65779 Kelkheim (DE). **SCHEUNEMANN, Karl-Heinz** [DE/DE]; Im Kohlruss 11, D-65835 Liederbach (DE). **GADEK, Thomas, R.** [US/US]; 2838 Chelsea Drive, Oakland, CA 94611 (US). **GOURVEST, Jean-François**

(54) Title: NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM



(57) Abstract: The present invention relates to compounds of formula (I), in which B, G, Z, X, Y, r, s and t have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by


WO 01/02398 A1

influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them

5

The present invention relates to compounds of the formula I,



- 10 in which B, G, X, Y, Z, r, s and t have the meanings indicated below, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin
15 receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to
20 processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

- Human bones are subject to a constant dynamic renovation process comprising bone
25 resorption and bone formation. These processes are controlled by types of cell specialized for these purposes. Bone resorption is based on the destruction of bone

matrix by osteoclasts. The majority of bone disorders are based on a disturbed equilibrium between bone formation and bone resorption. Osteoporosis is a disease characterized by low bone mass and enhanced bone fragility resulting in an increased risk of fractures. It results from a deficit in new bone formation versus bone resorption during the ongoing remodelling process. Conventional osteoporosis treatment includes, for example, the administration of bisphosphonates, estrogens, estrogen/progesterone (hormone replacement therapy or HRT), estrogen agonists/antagonists (selective estrogen receptor modulators or SERMs), calcitonin, vitamin D analogues, parathyroid hormone, growth hormone secretagogues, or sodium fluoride (Jardine et al., Annual Reports in Medicinal Chemistry 31 (1996) 211).

Activated osteoclasts are polynuclear cells having a diameter of up to 400 µm, which remove bone matrix. Activated osteoclasts become attached to the surface of the bone matrix and secrete proteolytic enzymes and acids into the so-called "sealing zone", the region between their cell membrane and the bone matrix. The acidic environment and the proteases cause the destruction of the bone. The compounds of the formula I inhibit bone resorption by osteoclasts.

Studies have shown that the attachment of osteoclasts to the bones is controlled by integrin receptors on the cell surface of osteoclasts. Integrins are a superfamily of receptors which include, inter alia, the fibrinogen receptor $\alpha_{IIb}\beta_3$ on the blood platelets and the vitronectin receptor $\alpha_v\beta_3$. The vitronectin receptor $\alpha_v\beta_3$ is a membrane glycoprotein which is expressed on the cell surface of a number of cells such as endothelial cells, cells of the vascular smooth musculature, osteoclasts and tumor cells. The vitronectin receptor $\alpha_v\beta_3$, which is expressed on the osteoclast membrane, controls the process of attachment to the bones and bone resorption and thus contributes to osteoporosis. $\alpha_v\beta_3$ in this case binds to bone matrix proteins such as osteopontin, bone sialoprotein and thrombospondin which contain the tripeptide motif Arg-Gly-Asp (or RGD).

Horton and coworkers describe RGD peptides and an anti-vitronectin receptor

antibody (23C6) which inhibit tooth destruction by osteoclasts and the migration of osteoclasts (Horton et al., *Exp. Cell. Res.* 195 (1991) 368). In *J. Cell Biol.* 111 (1990) 1713 Sato et al. describe echistatin, an RGD peptide from snake venom, as a potent inhibitor of bone resorption in a tissue culture and as an inhibitor of osteoclast adhesion to the bones. Fisher et al. (*Endocrinology* 132 (1993) 1411) and Yamamoto et al. (*Endocrinology* 139 (1998) 1411) were able to show in the rat that echistatin also inhibits bone resorption *in vivo*.

It was furthermore shown that the vitronectin $\alpha_v\beta_3$ on human cells of the vascular smooth musculature of the aorta stimulates the migration of these cells into the neointima which finally leads to arteriosclerosis and restenosis after angioplasty (Brown et al., *Cardiovascular Res.* 28 (1994) 1815). Yue et al. (*Pharmacology Reviews and Communications* 10 (1998) 9) show the inhibition of neointima formation using an $\alpha_v\beta_3$ antagonist.

Brooks et al. (*Cell* 79 (1994) 1157) showed that antibodies against $\alpha_v\beta_3$ or $\alpha_v\beta_3$ antagonists can cause a shrinkage of tumors by inducing the apoptosis of blood vessel cells during angiogenesis. The vitronectin receptor $\alpha_v\beta_3$ is also involved in the progression of a variety of other types of cancer, and is overexpressed in malignant melanoma cells (Engleman et al., *Annual Reports in Medicinal Chemistry* 31 (1996) 191). The melanoma invasiveness correlated with this overexpression (Stracke et al., *Encyclopedia of Cancer*, volume III, 1855, Academic Press, 1997; Hillis et al., *Clinical Science* 91 (1996) 639). Carron et al. (*Cancer Res.* 58 (1998) 1930) describe the inhibition of tumor growth and the inhibition of hypercalcemia of malignancy using an $\alpha_v\beta_3$ antagonist.

Friedlander et al. (*Science* 270 (1995) 1500) describe anti- $\alpha_v\beta_3$ antibodies or $\alpha_v\beta_3$ antagonists which inhibit the bFGF-induced angiogenesis processes in the rat eye, a property which can be used therapeutically in the treatment of retinopathies and in the treatment of psoriasis. Storgard et al. (*J. Clin. Invest.* 103 (1999) 47) describe the use of $\alpha_v\beta_3$ antagonists in the treatment of arthritic diseases.


Influencing of the vitronectin receptor or of the interactions in which it is involved thus offers the possibility of influencing different disease states for whose therapy and prophylaxis there continues to be a need for suitable pharmaceutical active ingredients.

5

EP-A-528586 and EP-A-528587 disclose aminoalkyl-substituted or heterocyclyl-substituted phenylalanine derivatives, and WO-A-95/32710 discloses aryl derivatives as inhibitors of bone resorption by osteoclasts. In WO-A-95/28426 RGD peptides are described as inhibitors of bone resorption, angiogenesis and restenosis. International

- 10 Patent Application PCT/EP98/08051 discloses carbamic ester derivatives, and International Patent Application PCT/EP99/00242 discloses sulfonamides which are vitronectin receptor antagonists. Further vitronectin receptor antagonists are disclosed in WO-A-98/08840 and WO-A-98/18461. Substituted purine derivatives as inhibitors of bone resorption are described in EP-A-853084. Further investigations
 15 have shown that the compounds of the formula I are particularly strong inhibitors of the vitronectin receptor and of bone resorption by osteoclasts.

The present invention relates to compounds of the formula I,



20

in which

G is a residue of the formula II

- 25 $-(CR^1R^2)_n-A-(CR^1R^2)_m-(CR^1R^3)_l-(CR^1R^2)_q-R^4$ II

A is a direct bond, -C(O)NR⁵-, -NR⁵C(O)-, -C(O)-, -NR⁵-, -O-, -S-, -S(O)-, -S(O)₂-, (C₂-C₄)-alkynediyl, (C₂-C₄)-alkenediyl, (C₅-C₁₄)-arylene where in the arylene residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur, or a divalent residue of a 3-

- 5 membered to 7-membered saturated or unsaturated ring which can contain one or two ring heteroatoms from the series consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by residues from the series consisting of =O, =S and R³;

 - 10 B is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₅-C₁₄)-arylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-
 - 15 (C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, aminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues B are independent of one another and can be identical or different;
- 20 X is hydrogen, NR⁶R^{6'}, fluorine, chlorine, bromine, OR⁶, SR⁶, hydroxy-(C₁-C₆)-alkyl-NH-, (hydroxy-(C₁-C₆)-alkyl)₂N-, amino-(C₁-C₆)-alkyl-NH-, (amino-(C₁-C₆)-alkyl)₂N-, hydroxy-(C₁-C₆)-alkyl-O-, hydroxy-(C₁-C₆)-alkyl-S- or -NH-C(O)-R⁶;
- 25 Y is R⁶, fluorine, chlorine, bromine, cyano, NR⁶R^{6'}, OR⁶, SR⁶ or hydroxy-(C₁-C₆)-alkyl-NH-;
- Z is N or CH;
- 30 R¹ and R² are hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶-S(O)_p-R⁷,

$R^6S(O)_2NHR^7$, $R^6OC(O)NHR^7$ or $R^6R^{6'}N-R^7$, where all residues R^1 and R^2 are independent of one another and can be identical or different;

- 5 R^3 is hydrogen, fluorine, chlorine, cyano, nitro, (C_1-C_{18})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14})-aryl, (C_5-C_{14})-aryl-(C_1-C_8)-alkyl-, (C_5-C_{14})-heteroaryl, (C_5-C_{14})-heteroaryl-(C_1-C_8)-alkyl-, R^6-O-R^7 , $R^6R^{6'}N-R^7$, $R^6C(O)-O-R^7$, $R^6C(O)R^7$, $R^6OC(O)R^7$, $R^6N(R^{6'})C(O)OR^7$, $R^6S(O)_pN(R^5)R^7$, $R^6OC(O)N(R^5)R^7$, $R^6C(O)N(R^5)R^7$, $R^6N(R^{6'})C(O)N(R^5)R^7$, $R^6N(R^{6'})S(O)_pN(R^5)R^7$, $R^6S(O)_pR^7$, $R^6SC(O)N(R^5)R^7$, $R^6N(R^{6'})C(O)R^7$ or $R^6N(R^{6'})S(O)_pR^7$, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by R^6 , fluorine, chlorine, bromine, cyano, trifluoromethyl, $R^6R^{6'}NR^7$, nitro, $R^6OC(O)R^7$, $R^6C(O)R^7$, $R^6N(R^{6'})C(O)R^7$, $R^6N(R^{6'})S(O)_pR^7$ or R^6-O-R^7 , and where all residues R^3 are independent of one another and can be identical or different;
- 10 R^4 is $-C(O)R^8$, $-C(S)R^8$, $-S(O)_pR^8$, $-P(O)R^8R^{8'}$ or a residue of a 4-membered to 8-membered saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms from the series consisting of nitrogen, oxygen and sulfur;
- 15 R^5 is hydrogen, (C_1-C_{10})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14})-aryl or (C_5-C_{14})-aryl-(C_1-C_8)-alkyl-, where all residues R^5 are independent of one another and can be identical or different;
- 20 R^6 and $R^{6'}$ are hydrogen, (C_1-C_{18})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14})-aryl, (C_5-C_{14})-aryl-(C_1-C_8)-alkyl-, (C_5-C_{14})-heteroaryl or (C_5-C_{14})-heteroaryl-(C_1-C_8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy, (C_1-C_6)-alkoxy-(C_1-C_6)-alkyl-, (C_1-C_6)-alkoxycarbonyl-, (C_1-C_6)-alkylcarbonyl-, (C_1-C_6)-alkylaminocarbonyl-, (C_1-C_6)-alkoxy-(C_1-C_6)-alkoxy-, (C_5-C_{14})-arylcarbonyl-, (C_5-C_{14})-aryl-(C_1-C_8)-alkylcarbonyl-, (C_1-C_6)-

alkanoylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl, (C₅-C₁₄)-

5 aryl and (C₅-C₁₄)-heteroaryl, and where all residues R⁶ and R^{6'} are independent of one another and can be identical or different;

R⁷ is (C₁-C₄)-alkanediyI or a direct bond, where all residues R⁷ are independent of one another and can be identical or different;

10

R⁸ and R^{8'} are hydroxy, (C₁-C₈)-alkoxy, (C₅-C₁₄)-aryl-(C₁-C₈)-alkoxy-, (C₅-C₁₄)-aryloxy, (C₁-C₈)-alkylcarbonyloxy-(C₁-C₄)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyloxy-(C₁-C₈)-alkoxy-, NR⁶R^{6'}, (di-((C₁-C₈)-alkyl)amino)carbonylmethyloxy-, (di-((C₅-C₁₄)-aryl-(C₁-C₈)-alkyl)amino)carbonylmethyloxy-, (C₅-C₁₄)-arylamino-, the

15 residue of an amino acid, N-((C₁-C₄)-alkyl)-piperidin-4-yloxy-, 2-methylsulfonylethoxy-, 1,3-thiazol-2-ylmethyloxy-, 3-pyridylmethyloxy-, 2-(di-((C₁-C₄)-alkyl)amino)-ethoxy or the residue Q⁻ (CH₃)₃N⁺-CH₂-CH₂-O- in which Q⁻ is a physiologically tolerable anion, where all residues R⁸ and R^{8'} are independent of one another and can be identical or different;

20

n is zero, one, two, three, four or five;

m is zero, one, two, three, four or five;

i is zero or one;

q is zero, one or two;

25 r is zero, one or two;

s is zero, one, two or three;

t is zero, one, two, three, four, five, six, seven or eight;

p is zero, one or two, where all numbers p are independent of one another and can be identical or different;

30

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

where, instead of the purine structure shown in formula I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present.

5

All residues and numbers (or indices) which can occur several times in the compounds of the formula I, for example the residues B, R¹, R², R³, R⁵, R⁶, R^{6'}, R⁷ or the number p but also all other residues and numbers to which this applies, can each independently of one another have the meanings indicated. They can all be identical 10 or different. Likewise, heteroatoms in heterocyclic rings or substituents in residues which can be present several times can in each case independently of one another have the meanings indicated and can all be identical or different.

Alkyl residues can be straight-chain or branched and can be saturated or mono-15 unsaturated or poly-unsaturated. This also applies if they carry substituents or occur as substituents on other residues, for example in alkoxy residues, alkoxycarbonyl residues or arylalkyl residues. Substituted alkyl residues can be substituted in any suitable position. Examples of alkyl residues containing from 1 to 18 carbon atoms are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, 20 dodecyl, tetradecyl, hexadecyl and octadecyl, the n-isomers of all these residues, isopropyl, isobutyl, isopentyl, neopentyl, isohexyl, isodecyl, 3-methylpentyl, 2,3,4-trimethylhexyl, sec-butyl, tert-butyl, or tert-pentyl. A preferred group of alkyl residues is formed by the residues methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

25

Unsaturated alkyl residues can contain one or more, for example one, two or three, double bonds and/or triple bonds. Of course, an unsaturated alkyl residue has to have at least two carbon atoms. Examples of unsaturated alkyl residues are alkenyl residues such as vinyl, 1-propenyl, allyl, butenyl or 3-methyl-2-butenyl, or alkynyl 30 residues such as ethynyl, 1-propynyl or propargyl. Alkyl residues can also be unsaturated when they are substituted. Preferably an unsaturated alkyl residue is mono-unsaturated and contains one double bond or triple bond.

The above statements relating to alkyl residues correspondingly apply to divalent residues like alkanediyl residues, alkenediyl residues, alkynediyl residues, alkylene residues, alkenylene residues, alkynylene residues. Thus, alkanediyl residues, 5 alkenediyl residues and alkynediyl residues can also be straight-chain or branched. The bonds via which the divalent residues are connected to their neighbouring groups can be located in any desired position. Examples of alkanediyl residues and alkylene residues are methylene (-CH₂-), methyl-methylene (1,1-ethanediyl) (-C(CH₃)H-), dimethyl-methylene (2,2-propanediyl) (-C(CH₃)₂-), 1,2-ethylene 10 (-CH₂-CH₂-), 1,3-propylene (-CH₂-CH₂-CH₂-) or 1,4-butylene (-CH₂-CH₂-CH₂-CH₂-). Examples of alkenylene residues are vinylene or propenylene, examples of alkynylene residues are ethynylene or propynylene.

Cycloalkyl residues can be monocyclic, bicyclic or tricyclic, i. e., they can be 15 monocycloalkyl residues, bicycloalkyl residues and tricycloalkyl residues, provided they have a suitable number of carbon atoms and the parent hydrocarbons are stable. A bicyclic or tricyclic cycloalkyl residue has to have at least 4 carbon atoms. Preferably a bicyclic or tricyclic cycloalkyl residue has at least 5 carbon atoms, more preferably at least 6 carbon atoms, and up to the number of carbon atoms specified 20 in the respective definition. Thus, (C₃-C₁₄)-cycloalkyl comprises but is not limited to, for example, (C₃-C₁₄)-monocycloalkyl, (C₆-C₁₄)-bicycloalkyl and (C₆-C₁₄)-tricycloalkyl, and (C₃-C₁₂)-cycloalkyl comprises but is not limited to, for example, (C₃-C₁₂)-monocycloalkyl, (C₆-C₁₂)-bicycloalkyl and (C₆-C₁₂)-tricycloalkyl.

25 Monocycloalkyl residues are, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl or cyclotetradecyl which can also be substituted by, for example, (C₁-C₄)-alkyl. Examples of substituted cycloalkyl residues which may be mentioned are 4-methylcyclohexyl and 2,3-dimethylcyclopentyl.

Bicycloalkyl residues and tricycloalkyl residues can likewise be unsubstituted or substituted in any desired suitable position, for example by one or more oxo groups

and/or one or more identical or different (C_1 - C_4)-alkyl groups, for example methyl or isopropyl groups, preferably methyl groups. The bond via which the bicyclic or the tricyclic residue is bonded can be located in any desired position in the molecule; the residue can thus be bonded via a bridgehead atom or an atom in a bridge. The bond 5 via which the residue is bonded can also be located in any desired stereochemical position, for example in an exo-position or an endo-position.

Examples of parent structures of bicyclic ring systems are norbornane (= bicyclo[2.2.1]heptane), bicyclo[2.2.2]octane and bicyclo[3.2.1]octane. An example 10 of a system substituted by an oxo group is camphor (= 1,7,7-trimethyl-2-oxobicyclo[2.2.1]heptane). Examples of parent structures of tricyclic systems are twistane (= tricyclo[4.4.0.0^{3,8}]decane, adamantane (= tricyclo[3.3.1.1^{3,7}]decane), noradamantane (= tricyclo[3.3.1.0^{3,7}]nonane), tricyclo[2.2.1.0^{2,6}]heptane, tricyclo[5.3.2.0^{4,9}]dodecane, tricyclo[5.4.0.0^{2,9}]undecane or 15 tricyclo[5.5.1.0^{3,11}]tridecane. A residue derived from adamantane can be 1-adamantyl or 2-adamantyl.

(C_5 - C_{14})-Aryl includes heterocyclic (C_5 - C_{14})-aryl residues (= (C_5 - C_{14})-heteroaryl residues) in which one or more of the 5 to 14 ring carbon atoms are replaced by 20 heteroatoms such as nitrogen, oxygen or sulfur, and carbocyclic (C_6 - C_{14})-aryl residues. Examples of carbocyclic (C_6 - C_{14})-aryl residues are phenyl, naphthyl such as 1-naphthyl or 2-naphthyl, biphenylyl such as 2-biphenylyl, 3-biphenylyl or 4-biphenylyl, anthryl or fluorenyl, where (C_6 - C_{12})-aryl residues, in particular 1-naphthyl, 2-naphthyl and phenyl, are preferred. If not stated otherwise, aryl residues, in 25 particular phenyl residues, can be unsubstituted or substituted by one or more, preferably one, two or three, identical or different substituents. In particular substituted aryl residues can be substituted by identical or different residues from the series consisting of (C_1 - C_8)-alkyl, in particular (C_1 - C_4)-alkyl, (C_1 - C_8)-alkoxy, in particular (C_1 - C_4)-alkoxy, fluorine, chlorine and bromine, nitro, amino, (C_1 - C_4)-30 alkylamino, di-((C_1 - C_4)-alkyl)amino, trifluoromethyl, hydroxy, methylenedioxy, cyano, hydroxycarbonyl-, aminocarbonyl-, (C_1 - C_4)-alkoxycarbonyl-, phenyl, phenoxy, benzyl, benzyloxy, tetrazolyl, (R^9O)₂P(O)- and (R^9O)₂P(O)-O- where R^9 is hydrogen, (C_1 -

C_{10})-alkyl, (C_6 - C_{14})-aryl or (C_6 - C_{14})-aryl-(C_1 - C_8)-alkyl. In general, only up to two nitro groups can be present in the compounds of formula I, and similarly all other groups, substituents or heteroatoms mentioned in the definition of the compounds of formula I can only be present in the compounds of formula I in such positions and in such numbers and in such combinations that the resulting molecule is stable and does not exhibit characteristics that are not desired for the intended use.

In monosubstituted phenyl residues the substituent can be located in the 2-position, the 3-position or the 4-position, the 3-position and the 4-position being preferred. If phenyl is disubstituted, the substituents can be in 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. Preferably in disubstituted phenyl residues the two substituents are arranged in 3,4-position relative to the linkage site. In trisubstituted phenyl residues, the substituents can be in 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-position, 2,4,6-position or 3,4,5-position. Similarly, naphthyl residues and other aryl residues can be substituted in any desired position, for example a 1-naphthyl residue in the 2-, 3-, 4-, 5-, 6-, 7- and 8-position, a 2-naphthyl residue in the 1-, 3-, 4-, 5-, 6-, 7- and 8-position.

Beside carbocyclic systems, (C_5 - C_{14})-aryl groups can also be monocyclic or polycyclic, for example monocyclic, bicyclic or tricyclic, aromatic ring systems in which 1, 2, 3, 4 or 5 ring carbon atoms are replaced by heteroatoms, in particular by identical or different heteroatoms from the series consisting of nitrogen, oxygen and sulfur. Examples of heterocyclic (C_5 - C_{14})-aryl groups and (C_5 - C_{14})-heteroaryl groups are pyridyl like 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrrolyl like 2-pyrrolyl and 3-pyrrolyl, furyl like 2-furyl and 3-furyl, thienyl like 2-thienyl and 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, β -carbolinyl, or benzo-fused, cyclopenta-fused, cyclohexa-fused or cyclohepta-fused derivatives of these residues. The heterocyclic systems can be substituted in any suitable position by the substituents listed above with respect carbocyclic aryl systems.

In the series of these heteroaryl groups, monocyclic or bicyclic aromatic ring systems which have 1, 2 or 3 ring heteroatoms, in particular 1 or 2 ring heteroatoms, from the series consisting of nitrogen, oxygen and sulfur and which can be unsubstituted or substituted by 1, 2 or 3 substituents from the series consisting of (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, fluorine, chlorine, nitro, amino, trifluoromethyl, hydroxy, (C₁-C₄)-alkoxycarbonyl-, phenyl, phenoxy, benzyloxy and benzyl, are preferred. Particularly preferred here are monocyclic or bicyclic aromatic 5-membered to 10-membered ring systems having 1, 2 or 3 heteroatoms, in particular having 1 or 2 ring heteroatoms, from the series consisting of nitrogen, oxygen and sulfur which can be substituted by 1 to 2 substituents from the series consisting of (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, phenyl, phenoxy, benzyl and benzyloxy. More particularly preferred are 5-membered or 6-membered monocyclic heteroaryl groups and 9-membered or 10-membered bicyclic heteroaryl groups containing 1 or 2, in particular 1, ring heteroatom from the series consisting of nitrogen, oxygen and sulfur which are unsubstituted or substituted as described before.

The above statements relating to aryl residues correspondingly apply to divalent arylene residues including heteroarylene residues. Arylene residues can be bonded to their neighbouring groups via any desired suitable positions. If an arylene residue is derived from a benzene ring the residue can be 1,2-phenylene, 1,3-phenylene or 1,4-phenylene, the latter two residues being preferred and 1,4-phenylene being especially preferred. If an arylene or heteroarylene residue is derived from a pyridine ring the two bonds via which it is connected can be in 1,2-position, 1,3-position or 1,4-position with respect to each other and in any desired position with respect to the ring nitrogen atom. Thus, a pyridinediyl residue can be, for example, 2,3-pyridinediyl, 2,4-pyridinediyl, 2,5-pyridinediyl, 2,6-pyridinediyl or 3,5-pyridinediyl. The above statements relating to aryl residues also correspondingly apply to the aryl moiety in groups like, for example, aryl-alkyl-. Examples of aryl-alkyl- residues which can also carry in the aryl moiety the substituents listed above, are benzyl, 1-phenylethyl or 2-phenylethyl.

The tetrahydro[1,8]naphthyridine ring depicted in formula I can be bonded to the 4-position of the 6-membered ring containing the group Z via any of the three positions in the aromatic ring, i. e. it can be a 5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl residue, a 5,6,7,8-tetrahydro[1,8]naphthyridin-3-yl residue or a 5,6,7,8-

- 5 tetrahydro[1,8]naphthyridin-4-yl residue. Preferably it is a 5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl residue or a 5,6,7,8-tetrahydro[1,8]naphthyridin-3-yl residue, particularly preferably a 5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl residue.

Examples of saturated and unsaturated rings, in particular of 3-membered to 7-

- 10 membered saturated or unsaturated rings which can contain one or two heteroatoms such as nitrogen, sulfur or oxygen and which can optionally be monosubstituted or disubstituted by residues from the series consisting of =O, =S and R³, are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, tetrahydropyran, 1,4-dioxacyclohexane, morpholine, 15 thiomorpholine, piperazine, piperidine, pyrrolidine, dihydroisoxazole, tetrahydroisoxazole, 1,3-dioxolane, 1,2-dithiolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, 2,3-dihydrothiophene, 2,5-dihydrothiophene, 2-imidazoline, 3-imidazoline, 4-imidazoline, 2-oxazoline, 3-oxazoline, 4-oxazoline, 2-thiazoline, 3-thiazoline, 4-thiazoline, thiazolidine, 2H-thiapyran, 2H-pyran, 4H-pyran.

20

The residue of an amino acid representing R⁸ or R^{8'} is obtained from the corresponding amino acid, as is customary in peptide chemistry, by formally removing a hydrogen atom from an amino group. This amino group is then linked in peptide fashion through an amide bond to the C(O) group in the group R⁸-C(O)-, to 25 the CS group in the group R⁸-CS-, etc. The amino acid from which R⁸ or R^{8'} can be derived can be a natural or unnatural amino acid and can be present in any stereochemical form, for example in the D form, the L form or in the form of a mixture of stereoisomers, for example in the form of a racemate. Preferred amino acids are α-amino acids and β-amino acids, α-amino acids being particularly preferred. 30 Suitable amino acids which may be mentioned include, but are not limited to, Aad, Abu, γAbu, ABz, 2ABz, εAca, Ach, Acp, Adpd, Ahb, Aib, βAib, Ala, βAla, ΔAla, Alg, All, Ama, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys,

(Cys)₂, Cyta, Daad, Dab, Dadd, Dap, Dapm, Dasu, Djen, Dpa, Dtc, Fel, Gln, Glu, Gly, Guv, hAla, hArg, hCys, hGln, hGlu, His, hIle, hLeu, hLys, hMet, hPhe, hPro, hSer, hThr, hTrp, hTyr, Hyl, Hyp, 3Hyp, Ile, Ise, Iva, Kyn, Lant, Lcn, Leu, Lsg, Lys, β Lys, Δ Lys, Met, Mim, Min, nArg, Nle, Nva, Oly, Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro,
5 Δ Pro, Pse, Pya, Pyr, Pza, Qin, Ros, Sar, Sec, Sem, Ser, Thi, β Thi, Thr, Thy, Thx, Tia, Tle, Tly, Trp, Trta, Tyr, Val, tert-butylglycine (Tbg), neopentylglycine (Npg), cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-thienylalanine (Thia), 2,2-diphenylaminoacetic acid, 2-(p-tolyl)-2-phenylaminoacetic acid, 2-(p-chlorophenyl)aminoacetic acid (cf. Houben-Weyl, Methoden der organischen Chemie
10 [Methods of Organic Chemistry], Volume 15/1 and 15/2, Georg Thieme Verlag, Stuttgart, 1974). Functional groups in amino acids can be present in protected form or can be derivatized. For example, a carboxylic acid group present in an amino acid can also be present in the form of an ester or amide such as, for example, methyl ester, ethyl ester, n-propyl ester, isopropyl ester, isobutyl ester, tert-butyl ester,
15 benzyl ester, unsubstituted amide, methylamide, ethylamide, ω -amino-(C₂-C₈)-alkylamide or semicarbazide. Examples of protective groups such as, for example, urethane protective groups, carboxyl protective groups and side-chain protective groups are Aloc, Pyoc, Fmoc, Tcboc, Z, Boc, Ddz, Bpoc, Adoc, Msc, Moc, Z(NO₂), Z(Hal_n), Bobz, Iboc, Adpoc, Mboc, Acm, tert-butyl, OBzl, ONbzl, OMbzl, Bzl, Mob,
20 Pic, Trt.

Optically active carbon atoms present in the compounds of the formula I can independently of one another have R configuration or S configuration. The compounds of the formula I can be present in the form of pure enantiomers or pure
25 diastereomers or in the form of mixtures of enantiomers, for example in the form of racemates, or of mixtures of diastereomers. The present invention relates to both pure enantiomers and mixtures of enantiomers as well as to pure diastereomers and mixtures of diastereomers. The invention comprises mixtures of two or of more than two stereoisomers of the formula I, and it comprises all ratios of stereoisomers in the
30 mixtures. Compounds of the formula I containing respective structural units can also be present as E isomers or Z isomers (or trans isomers or cis isomers). The invention relates to both pure E isomers, pure Z isomers, pure cis isomers, pure trans isomers

and to E/Z mixtures and cis/trans mixtures in all ratios. The invention also comprises all tautomeric forms of the compounds of the formula I. Diastereomers, including E/Z isomers, can be separated into the individual isomers, for example, by chromatography. Racemates can be separated into the two enantiomers by 5 customary methods, for example, by chromatography on chiral phases or by resolution, for example by crystallization of diastereomeric salts obtained with optically active acids or bases. Stereochemically uniform compounds of the formula I can also be obtained by employing stereochemically uniform starting materials or by using stereoselective reactions.

10

Physiologically tolerable salts of the compounds of formula I are nontoxic salts that are physiologically acceptable, in particular pharmaceutically utilizable salts. Such salts of compounds of the formula I containing acidic groups, for example carboxyl, are, for example, alkali metal salts or alkaline earth metal salts such as, for example, 15 sodium salts, potassium salts, magnesium salts and calcium salts, and also salts with physiologically tolerable quaternary ammonium ions and acid addition salts with ammonia and physiologically tolerable organic amines such as, for example, triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine. Basic groups in the compounds of the formula I can form acid addition salts, for example with inorganic 20 acids such as hydrochloric acid, sulfuric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. Compounds of the formula I which simultaneously contain a basic group and an acidic group, for example a carboxyl group in addition to basic nitrogen atoms, can 25 be present as zwitterions (or betaines or inner salts) which are likewise included by the present invention.

The physiologically tolerable anion Q⁻ which is contained in the compounds of the formula I in case R⁸ or R^{8'} is the 2-trimethylammonio-ethoxy- residue is, in particular, 30 a monovalent anion or an equivalent of a polyvalent anion of a nontoxic physiologically acceptable, in particular also pharmaceutically utilizable, inorganic or organic acid, for example the anion or an anion equivalent of one of the abovementioned acids

suitable for the formation of acid addition salts. Q⁻ can thus be, for example, one of the anions (or an anion equivalent) from the group comprising chloride, sulfate, phosphate, acetate, citrate, benzoate, maleate, fumarate, tartrate, methanesulfonate and p-toluenesulfonate.

5

Salts of compounds of the formula I can be obtained by customary methods known to those skilled in the art, for example by combining a compound of the formula I with an inorganic or organic acid or base in a solvent or diluent, or from other salts by cation exchange or anion exchange. A subject of the present invention are also all 10 salts of the compounds of the formula I which, because of low physiologically tolerability, are not directly suitable for use in pharmaceuticals but are suitable, for example, as intermediates for carrying out further chemical modifications of the compounds of the formula I or as starting materials for the preparation of physiologically tolerable salts.

15

The present invention moreover includes all solvates of compounds of the formula I, for example hydrates or adducts with alcohols, and also derivatives of the compounds of the formula I like esters, prodrugs and other physiologically tolerable derivatives, as well as active metabolites of the compounds of the formula I. The 20 invention relates in particular to prodrugs of the compounds of the formula I which can be converted into compounds of the formula I under physiological conditions. Suitable prodrugs for the compounds of the formula I, i. e. chemically modified derivatives of the compounds of the formula I having properties which are improved in a desired manner, are known to those skilled in the art. More detailed information 25 relating to prodrugs and their preparation is found, for example, in Fleisher et al., Advanced Drug Delivery Reviews 19 (1996) 115; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; or H. Bundgaard, Drugs of the Future 16 (1991) 443; which are all incorporated herein by reference. Suitable prodrugs for the compounds of the formula I are especially ester prodrugs and amide prodrugs of carboxylic acid groups, 30 in particular of a COOH group representing R⁴, for example alkyl esters, and also acyl prodrugs and carbamate prodrugs of acylatable nitrogen-containing groups such as amino groups or the tetrahydronaphthyridine group. In the acyl prodrugs or

carbamate prodrugs, one or more, for example one or two, hydrogen atoms on nitrogen atoms in such groups are replaced by an acyl group or a carbamate group.

Suitable acyl groups and carbamate groups for the acyl prodrugs and carbamate prodrugs are, for example, the groups R^{10} -C(O)- and $R^{11}O$ -C(O)-, in which R^{10} is


- 5 hydrogen, (C_1-C_{18})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14})-aryl in which 1 to 5 carbon atoms can be replaced by heteroatoms such as nitrogen, oxygen or sulfur, or (C_5-C_{14})-aryl-(C_1-C_8)-alkyl- in which 1 to 5 carbon atoms in the aryl moiety can be replaced by heteroatoms such as nitrogen, oxygen or sulfur, and in which R^{11} has the meanings indicated for R^{10} with the exception of hydrogen.

10


The present invention is furthermore not restricted to the compounds shown in formula I which contain an actual purine substructure but also includes those analogous compounds which instead of the purine substructure shown in formula I contain a 3-deazapurine substructure, 7-deazapurine substructure or 7-deaza-8-

- 15 azapurine substructure, i. e. those compounds which instead of the actual purine ring system contain one of the ring systems of formula IIIa, formula IIIb or formula IIIc wherein the 6-membered ring which contains the group Z and to which the tetrahydronaphthyridine residue is bonded is symbolized by the circular arc attached to the group Z. All the above and following explanations relating to compounds of the


20



IIIa



IIIb



IIIc


formula I correspondingly apply to these compounds. Unless stated otherwise, if compounds of the formula I are being discussed then the deaza analogs and deaza-25 aza analogs are also included. Preferably, in the compounds of the invention the actual purine structure shown in formula I is present, in which the nitrogen atoms in

the 3-position and in the 7-position are actually present and a carbon atom to which the group Y is bonded is actually present in the 8-position.

The rings in the compounds of formula I which can carry substituents B, i. e. the 5 aromatic ring and the non-aromatic ring in the tetrahydronaphthyridine moiety and the 6-membered ring containing the group Z, can independently of one another be unsubstituted or substituted where in substituted rings the substituents can be present in any desired position. If any of these rings is unsubstituted this means that the respective number r or s or t indicating the number of substituents B is zero. In 10 such a case, i. e. if any of the rings is unsubstituted and the respective number r, s or t is zero, all positions on that ring which are not occupied by bonds connecting it to the neighbouring groups which are depicted in formula I, carry hydrogen atoms. If any of the rings is substituted this means that it carries one or more groups or atoms different from hydrogen from the group and atoms listed in the definition of B, and 15 that the respective number r, s or t is different from zero. In such a case, i. e. if any of the rings is substituted and the respective number r, s or t is different from zero, all positions on that ring which are not occupied by substituents B or by bonds connecting it to neighbouring groups depicted in formula I carry hydrogen atoms. For example, the aromatic ring in the tetrahydronaphthyridine moiety has three positions 20 to which neighbouring groups or substituents can be bonded. One of these positions is occupied by the bond connecting the ring to the 6-membered ring containing the group Z. If r is zero or one or two then the remaining two positions in the aromatic ring carry two hydrogen atoms and no substituent B, or one hydrogen atom and one substituent B, or no hydrogen atom and two substituents B, respectively. The number 25 r preferably is zero or one, more preferably zero. The number s preferably is zero, one or two, more preferably zero. The number t preferably is zero, one, two, three or four, more preferably zero, one or two, particularly preferably zero. In a preferred embodiment of the invention r, s and t simultaneously are zero, i. e. the aromatic ring and the non-aromatic ring in the tetrahydronaphthyridine moiety as well as the 6- 30 membered ring containing the group Z do not carry any substituents B but all positions not occupied by bonds to neighbouring groups depicted in formula I carry hydrogen atoms. The compounds of this preferred embodiment of the invention can

thus be represented by the formula Ia. In a particularly preferred embodiment of the invention the tetrahydronaphthyridine residue is connected to the 6-membered ring containing the group Z via its 2-position leading to compounds of the formula Ib. In formulae Ia and Ib G, X, Y and Z have the meanings given above for formula I.

5



Ia

Ib

The number n preferably is zero, one or two, more preferably one.

10 The number m preferably is zero or one, more preferably zero.

The number i preferably is one.

The number q preferably is zero or one, more preferably zero.

15

Preferably in the compounds of formula I at least one of the numbers n, m, i and q is different from zero.

20 The group A preferably is a direct bond, i. e. the groups $(CR^1R^2)_n$ and $(CR^1R^2)_m$ are preferably bonded directly to one another.

The groups B preferably are independently of one another hydroxy or (C_1-C_6) -alkyl, more preferably hydroxy or (C_1-C_4) -alkyl.

The group X preferably is hydrogen, NR⁶R^{6'}, hydroxy-(C₁-C₆)-alkyl- or -NH-C(O)-R⁶, more preferably hydrogen, NR⁶R^{6'} or -NH-C(O)-R⁶, particularly preferably hydrogen or NH₂, more particularly preferably hydrogen.

- 5 The group Y preferably is hydrogen.

The group Z preferably is N, i. e. a nitrogen atom.

- The residues R¹ and R² preferably are independently of one another hydrogen or (C₁-C₂)-alkyl, more preferably hydrogen or methyl, particularly preferably hydrogen.

- The residues R³ preferably are independently of one another R⁶R^{6'}N-R⁷, R⁶OC(O)N(R⁵)R⁷, R⁶S(O)_pN(R⁵)R⁷, R⁶C(O)N(R⁵)R⁷ or R⁶N(R^{6'})C(O)N(R⁵)R⁷ where p here is 1 or 2 and preferably p here is 2. More preferably R³ is R⁶OC(O)N(R⁵)R⁷ or 15 R⁶S(O)_pN(R⁵)R⁷ where p here is 1 or 2 and preferably p here is 2. Particularly preferably R³ is R⁶OC(O)N(R⁵)R⁷ or R⁶S(O)₂N(R⁵)R⁷. As stated above, in general the compounds of the present invention preferably exhibit a suitable degree of stability for the intended use. Therefore, in groups like R⁶OC(O)N(R⁵)R⁷, R⁶S(O)_pN(R⁵)R⁷ and 20 R⁶S(O)₂N(R⁵)R⁷ the residue R⁶ preferably has one of the above meanings but does not denote hydrogen. In a preferred embodiment of the present invention the compounds of the formula I contain a lipophilic residue in the group R³. A group of such preferred compounds is formed, for example, by those compounds in which R⁶ and/or R^{6'}, for example in the group R⁶OC(O)N(R⁵)R⁷ or R⁶S(O)₂N(R⁵)R⁷, is (C₄-C₁₄)-alkyl, (C₅-C₁₄)-aryl-(C₁-C₄)-alkyl-, for example benzyl, (C₅-C₁₄)-cycloalkyl or (C₅-C₁₄)-25 cycloalkyl-(C₁-C₄)-alkyl-, preferred cycloalkyl residues here in particular being the 1-adamantyl residue and the 2-adamantyl residue, or is (C₅-C₁₄)-aryl which is substituted with fluorine, chlorine or bromine, preferably chlorine, trifluoromethyl, (C₁-C₆)-alkyl or (C₁-C₆)-alkoxy.
- 30 R⁴ preferably is -C(O)-R⁸. The residue of a 4-membered to 8-membered heterocycle representing R⁴ preferably is one of the residues tetrazolyl, imidazolyl, pyrazolyl, oxazolyl and thiadiazolyl.

The residues R⁵ preferably are independently of one another hydrogen or (C₁-C₄)-alkyl, more preferably hydrogen or (C₁-C₂)-alkyl, particularly preferably hydrogen.

- 5 The residues R⁷ preferably are independently of one another a direct bond or (C₁-C₂)-alkanediyI, more preferably a direct bond.

The residues R⁸ and R^{8'} preferably are independently of one another hydroxy or (C₁-C₈)-alkoxy, more preferably hydroxy or (C₁-C₆)-alkoxy, particularly preferably hydroxy

- 10 or (C₁-C₄)-alkoxy.

Preferred compounds of the present invention are those compounds of the formula I in which one or more of the residues have preferred definitions, or have one or more specific denotations of the lists of denotations given in their respective definitions and 15 in the general explanations on residues, all combinations of such preferred definitions and specific denotations being a subject of the present invention.

A group of preferred compounds is formed, for example, by compounds of the formula I in which

20

G is a residue of the formula II



- 25 A is a direct bond, -C(O)NR⁵-, -NR⁵C(O)-, -C(O)-, -NR⁵-, -O-, -S-, -S(O)-, -S(O)₂-, (C₂-C₄)-alkynediyl, (C₂-C₄)-alkenediyI, (C₅-C₁₄)-arylene where in the arylene residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur, or a divalent residue of a 3-membered to 7-membered saturated or unsaturated ring which can 30 contain one or two ring heteroatoms from the series consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by residues from the series consisting of =O, =S and R³;

B is (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkylcarbonyl-, (C₅-C₁₄)-arylcyclononyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl- (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues B are independent of one another and can be identical or different;

X is hydrogen, NH₂, -NH-C(O)-R⁶ or OH;

Y is hydrogen;

15

Z is N;

R¹ and R² independently of one another are hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶S(O)₂NHR⁷, R⁶OC(O)NHR⁷ or R⁶R^{6'}N-R⁷, where all residues R¹ and R² are independent of one another and can be identical or different;

R³ is hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶R^{6'}N-R⁷, R⁶C(O)-O-R⁷, R⁶C(O)R⁷, R⁶OC(O)R⁷, R⁶N(R^{6'})C(O)OR⁷, R⁶S(O)_pN(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷, R⁶C(O)N(R⁵)R⁷, R⁶N(R^{6'})C(O)N(R⁵)R⁷, R⁶N(R^{6'})S(O)_pN(R⁵)R⁷, R⁶S(O)_pR⁷, R⁶SC(O)N(R⁵)R⁷, R⁶N(R^{6'})C(O)R⁷ or R⁶N(R^{6'})S(O)_pR⁷, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl and heteroaryl can be monosubstituted or polysubstituted by R⁶, fluorine, chlorine, bromine, cyano,

trifluoromethyl, $R^6R^{6'}NR^7$, nitro, $R^6OC(O)R^7$, $R^6C(O)R^7$, $R^6N(R^{6'})C(O)R^7$, $R^6N(R^{6'})S(O)_pR^7$ or R^6-O-R^7 , and where all residues R^3 are independent of one another and can be identical or different;

5 R^4 is $-C(O)R^8$ or $-P(O)R^8R^{8'}$;

R^5 is hydrogen, (C_1-C_{10})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl- or (C_5-C_{14})-aryl-(C_1-C_8)-alkyl-, where all residues R^5 are independent of one another and can be identical or different;

10

R^6 and $R^{6'}$ are hydrogen, (C_1-C_{12})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14})-aryl, (C_5-C_{14})-aryl-(C_1-C_8)-alkyl-, (C_5-C_{14})-heteroaryl or (C_5-C_{14})-heteroaryl-(C_1-C_8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the

15 series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy, (C_1-C_6)-alkoxy-(C_1-C_6)-alkyl-, (C_5-C_{14})-arylcarbonyl-, (C_5-C_{14})-aryl-(C_1-C_6)-alkylcarbonyl-, (C_1-C_6)-alkanoylamino-, (C_5-C_{14})-arylsulfonylamino-, (C_1-C_6)-alkylsulfonylamino-, (C_1-C_6)-alkylamino-, di-((C_1-C_6)-alkyl)amino-, (C_1-C_6)-alkylsulfonyl-, (C_5-C_{14})-aryl and (C_5-C_{14})-heteroaryl, and where
20 all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

R^7 is (C_1-C_4)-alkanediyil or a direct bond, where all residues R^7 are independent of one another and can be identical or different;

25

R^8 and $R^{8'}$ are hydroxy, (C_1-C_8)-alkoxy, (C_5-C_{14})-aryl-(C_1-C_8)-alkoxy-, (C_1-C_8)-alkylcarbonyloxy-(C_1-C_4)-alkoxy- or $NR^6R^{6'}$ where all residues R^8 and $R^{8'}$ are independent of one another and can be identical or different;

30 n is zero, one, two, three, four or five;
m is zero, one, two, three, four or five;

i is zero or one;

q is zero, one or two;

r is zero, one or two;

s is zero, one, two or three;

5 t is zero, one, two, three, four, five, six, seven or eight;

p is zero, one or two, where all numbers p are independent of one another and can be identical or different;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their

10 physiologically tolerable salts and their prodrugs;

where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure are not included.

15

A group of more preferred compounds is formed, for example, by compounds of the formula I in which

G is a residue of the formula II

20



A is a direct bond, -C(O)NR⁵-, -NR⁵C(O)-, -C(O)-, -NR⁵-, -O-, -S(O)₂-, (C₂-C₄)-alkynediyl, (C₂-C₄)-alkenediyl or (C₅-C₁₄)-arylene where in the arylene residue one,

25 two or three ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur;

B is (C₁-C₆)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₄)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₄)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-,

30 fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylcarbonyl-, (C₅-C₁₄)-arylcarbonyl-, (C₁-C₆)-alkanoylamino-,

25

(C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl,
where all residues B are independent of one another and can be identical or different;

X is hydrogen, NH₂ or -NH-C(O)-R⁶;

5

Y is hydrogen;

Z is N;

10 R¹ and R² are hydrogen, fluorine, chlorine, cyano, (C₁-C₄)-alkyl, (C₃-C₁₄)-cycloalkyl,
(C₃-C₁₄)-cycloalkyl-(C₁-C₄)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₄)-alkyl-, (C₅-C₁₄)-
heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, R⁶S(O)₂NHR⁷ or R⁶OC(O)NHR⁷, where
all residues R¹ and R² are independent of one another and can be identical or
different;

15

R³ is hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-
C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-
heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶R^{6'}N-R⁷, R⁶C(O)R⁷,

R⁶N(R^{6'})C(O)OR⁷, R⁶S(O)_pN(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷, R⁶C(O)N(R⁵)R⁷,

20 R⁶N(R^{6'})C(O)N(R⁵)R⁷, R⁶N(R^{6'})S(O)_pN(R⁵)R⁷, R⁶S(O)_pR⁷, R⁶N(R^{6'})C(O)R⁷ or
R⁶N(R^{6'})S(O)_pR⁷, where alkyl can be mono-unsaturated or poly-unsaturated and
where alkyl, cycloalkyl, aryl and heteroaryl can be monosubstituted or polysubstituted
by R⁶, fluorine, chlorine, bromine, cyano, trifluoromethyl, R⁶R^{6'}NR⁷, R⁶C(O)R⁷,
R⁶N(R^{6'})C(O)R⁷, R⁶N(R^{6'})S(O)_pR⁷ or R⁶-O-R⁷;

25

R⁴ is -C(O)R⁸;

R⁵ is hydrogen or (C₁-C₄)-alkyl, where all residues R⁵ are independent of one another
and can be identical or different;

30

R⁶ and R^{6'} are hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the

5 series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl, and where all residues R⁶ and R^{6'} are independent of one another and can be identical or different;

10 R⁷ is (C₁-C₂)-alkanediyl or a direct bond, where all residues R⁷ are independent of one another and can be identical or different;

R⁸ is hydroxy or (C₁-C₈)-alkoxy;

15 n is zero, one, two, three, four or five;

m is zero or one;

i is zero or one;

q is zero or one;

r is zero, one or two;

20 s is zero, one or two;

t is zero, one, two, three or four;

p is zero, one or two, where all numbers p are independent of one another and can be identical or different;

25 in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;


where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine

30 structure are not included.

A group of particularly preferred compounds is formed, for example, by compounds

of the formula I in which

G is a residue of the formula II



A is a direct bond, $-\text{C}(\text{O})\text{NR}^5-$, $-\text{NR}^5\text{C}(\text{O})-$, $-\text{C}(\text{O})-$, $-\text{NR}^5-$ or (C_5 - C_{14})-arylene where in the arylene residue one or two ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur;

10

B is (C₁-C₆)-alkyl, chlorine, hydroxy, cyano, trifluoromethyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylamino- or di-((C₁-C₆)-alkyl)amino-, where all residues B are independent of one another and can be identical or different;

15

X is hydrogen;

Y is hydrogen:

20 Z is N:

R^1 and R^2 are hydrogen, (C_1-C_4) -alkyl, $R^6S(O)_2NHR^7$ or $R^6OC(O)NHR^7$, where all residues R^1 and R^2 are independent of one another and can be identical or different.

25 R³ is hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₆)-alkyl-,
(C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₆)-alkyl-, R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷, where
alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl
and heteroaryl can be monosubstituted or polysubstituted by R⁶, fluorine, chlorine,
30 trifluoromethyl, R⁶C(O)R⁷ or R⁶-O-R⁷;

R^4 is $-C(O)R^8$;

R^5 is hydrogen or (C_1 - C_4)-alkyl, where all residues R^5 are independent of one another and can be identical or different;

- 5 R^6 and $R^{6'}$ are hydrogen, (C_1 - C_{12})-alkyl, (C_3 - C_{14})-cycloalkyl, (C_3 - C_{14})-cycloalkyl-(C_1 - C_8)-alkyl-, (C_5 - C_{14})-aryl, (C_5 - C_{14})-aryl-(C_1 - C_8)-alkyl-, (C_5 - C_{14})-heteroaryl or (C_5 - C_{14})-heteroaryl-(C_1 - C_8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C_1 - C_6)-alkyl,
10 (C_1 - C_6)-alkoxy, (C_1 - C_6)-alkylamino-, di-((C_1 - C_6)-alkyl)amino-, (C_5 - C_{14})-aryl and (C_5 - C_{14})-heteroaryl, and where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

- 15 R^7 is (C_1 - C_2)-alkanediyI or a direct bond, where all residues R^7 are independent of one another and can be identical or different;

R^8 is hydroxy or (C_1 - C_6)-alkoxy;

n is zero, one, two, three, four or five;

20 m is zero or one;

i is zero or one;

q is zero or one;

r is zero or one;

s is zero, one or two;

25 t is zero, one, two, three or four;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

- 30 where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure are not included.

A group of more particularly preferred compounds is formed, for example, by compounds of the formula I in which

5 G is a residue of the formula II



A is a direct bond;

10

B is (C₁-C₆)-alkyl or hydroxy, where all residues B are independent of one another and can be identical or different;

X is hydrogen;

15

Y is hydrogen;

Z is N;

20 R¹ and R² are hydrogen, (C₁-C₄)-alkyl, R⁶S(O)₂NHR⁷ or R⁶OC(O)NHR⁷, where all residues R¹ and R² are independent of one another and can be identical or different;

R³ is hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₆)-alkyl-, R⁶R⁶'N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl and heteroaryl can be monosubstituted or polysubstituted by R⁶, fluorine, chlorine, trifluoromethyl, R⁶C(O)R⁷ or R⁶-O-R⁷;

25 30 R⁴ is -C(O)R⁸;

R⁵ is hydrogen or (C₁-C₄)-alkyl;

R⁶ and R^{6'} are hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be

- 5 substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl, and where all residues R⁶ and R^{6'} are independent of one another and can be identical or different;

10

R⁷ is a direct bond;

R⁸ is hydroxy or (C₁-C₄)-alkoxy;

15 n is zero, one or two;

m is zero or one;

i is zero or one;

q is zero or one;

r is zero or one;

20 s is zero, one or two;

t is zero;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

25

where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure are not included.

- 30 A group of especially preferred compounds is formed, for example, by compounds of the formula I in which

G is a residue of the formula II



5 A is a direct bond;

X is hydrogen;

Y is hydrogen;

10

Z is N;

R¹ and R² are hydrogen or (C₁-C₂)-alkyl, where all residues R¹ and R² are independent of one another and can be identical or different;

15

R³ is R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷;

R⁴ is -C(O)R⁸;

20 R⁵ is hydrogen or (C₁-C₂)-alkyl;

R⁶ and R^{6'} are hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be

25 substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl, and where the residues R⁶ and R^{6'} are independent of one another and can be identical or different;

30

R⁷ is a direct bond;

R⁸ is hydroxy or (C₁-C₄)-alkoxy;

n is zero, one or two;

m is zero or one;

5 i is zero or one;

q is zero or one;

r is zero;

s is zero;

t is zero;

10

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

where in this group of compounds the analogs of the compounds of formula I having

15 a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure are not included.

A group of more especially preferred compounds is formed, for example, by compounds of the formula I in which

20

G is a residue of the formula II



25 A is a direct bond;

X is hydrogen;

Y is hydrogen;

30

Z is N;

R¹ and R² are hydrogen;

R³ is R⁶S(O)₂N(R⁵)R⁷ or R⁶OC(O)N(R⁵)R⁷;

5 R⁴ is -C(O)R⁸;

R⁵ is hydrogen;

10 R⁶ is (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

15

R⁷ is a direct bond;

R⁸ is hydroxy or (C₁-C₄)-alkoxy;

20 n is one;

m is zero;

i is one;

q is zero;

r is zero;

25 s is zero;

t is zero;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

30

where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine

structure are not included.

Further, preferred compounds of the formula I are those in which, in case the number i is one, the residue R¹ in the group (CR¹R³)_i is hydrogen and the residue R³ is an amino group or a substituted amino group, the chiral carbon atom carrying the residue R³ has S configuration, and their physiologically tolerable salts and their prodrugs, where with respect to other stereoisomeric centers these compounds can be present in all their stereoisomeric forms and mixtures thereof in all ratios.

Examples of residues R³ that can be present in these preferred compounds of the


formula I are the residues R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷ wherein R⁷ is a direct bond. In particular in compounds of the formula I in which the numbers m and q are zero, the numbers i and n are one, A is a direct bond, R¹ and R² are hydrogen, R³ is one of the residues R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷, and R⁷ is a direct bond, i. e. for example in the compounds which form the above-defined group of more especially preferred compounds, the chiral carbon atom carrying the residue R³ preferably has S configuration.

The present invention also relates to processes of preparation by which the

compounds of the formula I are obtainable and which comprise carrying out one or more of the synthesis steps described below. The compounds of the formula I can generally be prepared, for example in the course of a convergent synthesis, by linkage of two or more fragments which can be derived retrosynthetically from the formula I. In the preparation of the compounds of the formula I it can generally be advantageous or necessary in the course of the synthesis to introduce functional groups which could lead to undesired reactions or side reactions in the respective synthesis step in the form of precursor groups which are later converted into the desired functional groups, or to temporarily block functional groups by a protective group strategy suited to the synthesis problem. Such strategies are well known to those skilled in the art (see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, Wiley, 1991). As examples of precursor groups nitro groups and cyano groups may be mentioned which can later be converted by reduction, for

example by catalytic hydrogenation, into amino groups and aminomethyl groups, respectively. The protective groups exemplarily mentioned above with respect to functional groups in amino acid residues present in the compounds of formula I correspondingly can be used as protective groups for functional groups during the synthesis of the compounds of formula I.

For example, for the preparation of a compound of the formula I a building block of the formula IV



10


in which L^1 is a customary nucleophilically substitutable leaving group, can be used. Suitable groups L^1 are known to those skilled in the art and can be, for example chlorine, bromine, iodine, or a sulfonyloxy group like p-toluenesulfonyloxy (-OTos),
15 methanesulfonyloxy (-OMes) or trifluoromethanesulfonyloxy (-OTf), preferably chlorine or bromine. X and Y in the compounds of formula IV are as defined above but functional groups can optionally also be present in the form of precursor groups or can be protected by customary protective groups. The compound of the formula IV is reacted with a building block of the formula V

20



wherein R^1 , R^2 , R^3 , R^4 , A, n, m, i and q are as defined above but wherein functional groups can optionally also be present in the form of precursor groups or can be
25 protected by customary protective groups. In particular the group R^4 in a compound of the formula V can be a precursor group or a protected form of the final group R^4 that is to be present in the target compound of the formula I to be prepared. For

example, a group R⁴ is a compound of the formula I denoting hydroxycarbonyl (-COOH) is preferably present in a compound of the formula V as a tert-butyl ester or a methyl ester or an ethyl ester group. The group L² in the compounds of formula V is hydroxy or a customary nucleophilically substitutable leaving group. Suitable leaving groups L² are known to those skilled in the art and can be, for example chlorine, bromine, iodine, -OTos, -OMes or -OTf. From the compounds of formulae IV and V a compound of formula VI




10

is obtained wherein G, X, Y and L¹ are as defined above but wherein functional groups can optionally also be present in the form of precursor groups or can be protected by customary protective groups. The reaction of the compounds of formula IV and V can be carried out according to methods known to those skilled in the art (see, for example, J. March, Advanced Organic Chemistry, Fourth Edition, Wiley, 1992, and source literature quoted therein). Preferably, the reaction is carried out in a suitable organic solvent or diluent, for example dichloromethane (DCM), chloroform, tetrahydrofuran (THF), diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-butyl ether, acetonitrile, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dioxane, toluene, benzene, ethyl acetate or a mixture of these solvents, if appropriate with addition of a base such as, for example, butyllithium, lithium diisopropylamide (LDA), sodium hydride, sodium amide, potassium tert-butoxide, calcium carbonate, cesium carbonate, triethylamine, N,N-diisopropylethylamine or complex bases (for example sodium amide together with an alcoholate R²⁵ONa, where R²⁵ is (C₂-C₆)-alkyl or CH₃CH₂OCH₂CH₂-). With compounds of the formula V in which L² is hydroxy the reaction is carried out after activation of the hydroxy group, for example by reaction with triphenylphosphine and

diethyl azodicarboxylate (DEAD) in THF under the conditions of the well-known Mitsunobu reaction.

For the preparation of a compound of the formula I in which Z is nitrogen a

- 5 compound of the formula VI is then reacted with a compound of the formula VIIa,




wherein B, r, s and t are defined as above but wherein functional groups can

- 10 optionally also be present in the form of precursor groups or can be protected by customary protective groups. The reaction of the compounds of the formulae VI and VIIa can be carried out according to methods well-known to those skilled in the art (see, for example, J. March, Advanced Organic Chemistry, Fourth Edition, Wiley, 1992, and source literature quoted therein). In the reaction of a compound of the
15 formula VI with a compound of the formula VIIa a nucleophilically substitutable leaving group in one reaction partner is replaced with a nucleophilic nitrogen atom in the other reaction partner as in the case of the reaction of the compounds of formulae IV and V. The above explanations on solvents or bases suitable for the reaction of the compounds of formula IV and V therefore correspondingly apply to the
20 reaction of the compounds of formulae VI and VIIa. As a base in the reaction of the compounds of formulae VI and VIIa also an excess of the compound of formula VIIa can be used.


For the preparation of a compound of the formula I in which Z is CH a compound of

- 25 the formula VI is reacted with a compound of the formula VIIb,



wherein B, r, s and t are defined as above but wherein functional groups can optionally also be present in the form of precursor groups or can be protected by customary protective groups. The reaction of the compounds of the formulae VI and VIIb can be carried out under the conditions of the Stille coupling as described, for example, in Langli et al., Tetrahedron 52 (1996) 5625 or Gundersen, Tetrahedron Lett. 35 (1994) 3153, or under the conditions of the Heck coupling as described, for example, in Koyama et al., Nucleic Acids Res., Symp. Ser. 11 (1982) 41 which are all incorporated herein by reference.

The reaction of a compound of the formula VI with a compound of the formula VIIa or VIIb, respectively, leads to a compound of the formula VIII,



15

wherein B, G, X, Y, Z, r, s and t are defined as above but wherein functional groups can optionally also be present in the form of precursor groups or can be protected by customary protective groups. Protective groups optionally still present in the compounds of the formula VIII are then removed by standard processes. For example, tert-butyl ester groups, especially a tert-butyl ester group which represents the group R⁴ in the group G in the compound of formula VIII and which is a protected

form of hydroxycarbonyl group representing R⁴ in the target compound of formula I, can be converted into the carboxylic acid groups by treatment with trifluoroacetic acid. Benzyl groups can be removed by hydrogenation. Fluorenylmethoxycarbonyl groups can be removed by secondary amines. If desired, further reactions can then
5 be carried out by standard processes, for example acylation reactions or sulfonylation reactions of amino groups or esterification reactions. Further, for example, a substituent X in the 2-position of the purine structure can also be introduced at the end of the above-described synthesis of the compounds of formula I by known methods per se, for example as described in D. A. Nugiel, J. Org. Chem. 62 (1997)
10 201 or N. S. Gray, Tetrahedron Lett. 38 (1997) 1161 and the references quoted therein, and a substituent Y in the 8-position can be introduced by methods known per se as described, for example, in E. J. Reist et al., J. Org. Chem. 33 (1968) 1600; J. L. Kelley et al., J. Med. Chem. 33 (1990) 196 or E. Vanotti et al., Eur. J. Chem. 29
15 (1994) 287 which are all incorporated herein by reference. In addition, if desired a compound of the formula VIII or a compound obtained from a compound of the formula VIII can be converted into a physiologically tolerable salt or a prodrug by processes known per se to those skilled in the art.

In the synthesis of a compound of the formula I it is also possible first to react a
20 compound of the formula IV with a compound of the formula VIIa or VIIb leading to replacement of the group L¹ in the formula IV by the naphthyridinyl-substituted 6-membered ring, and subsequently to react the resulting intermediate with a compound of the formula V.

25 The starting compounds of the formulae IV, V, VIIa and VIIb which are linked to give the compounds of the formula I, are commercially available or can be prepared by or analogously to processes described below or in the literature.

The compounds of the formula I are valuable pharmacologically active compounds
30 which are suitable, for example, for the therapy and prophylaxis of bone disorders, tumor diseases, cardiovascular disorders or inflammatory conditions. The compounds of the formula I and their physiologically tolerable salts and their

prodrugs can be administered to animals, preferably to mammals, and in particular to humans as pharmaceuticals for therapy or prophylaxis. They can be administered on their own or in mixtures with one another or in the form of pharmaceutical compositions or pharmaceutical preparations which permit enteral or parenteral

- 5 administration and which, as active constituent, contain an efficacious dose of at least one compound of the formula I and/or its physiologically tolerable salts and/or its prodrugs in addition to customary pharmaceutically acceptable carrier substances and/or additives.
- 10 The present invention therefore also relates to the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for use as pharmaceuticals, to the use of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for the production of pharmaceuticals for the therapy and prophylaxis of the diseases mentioned above or below, for example for the therapy and prophylaxis of bone disorders, and also to the use of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for the therapy and prophylaxis of these diseases and to methods for such therapy and prophylaxis. The present invention furthermore relates to pharmaceutical compositions (or pharmaceutical preparations) which contain an efficacious dose of at least one compound of the formula I and/or its physiologically tolerable salts and/or its prodrugs and a customary pharmaceutically acceptable carrier.
- 20

The pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration, however, can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions emulsions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.

The pharmaceutical compositions according to the invention are prepared in a

manner known per se and familiar to those skilled in the art, one or more compound(s) of the formula I and/or its (their) physiologically tolerable salts and/or its (their) prodrugs being mixed with one or more pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives and, if desired, one or 5 more other pharmaceutically active compounds and being brought into a suitable administration form and dosage form that can be used in human or veterinary medicine. For the production of pills, tablets, coated tablets and hard gelatin capsules it is possible to use, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts, etc. Carriers for soft gelatin capsules and suppositories are, 10 for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carrier substances for the production of solutions, for example injection solutions, or of emulsions or syrups are, for example, water, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc. Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and 15 lactic acid. The pharmaceutical compositions normally contain about 0.5 to 90 % by weight of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs. The amount of the active ingredient of the formula I and/or its physiologically tolerable salts and/or its prodrugs in the pharmaceutical compositions normally is about 0.2 mg to about 500 mg, preferably about 1 mg to about 200 mg.

20 In addition to the active ingredients of the formula I and/or its physiologically tolerable salts and/or its prodrugs and carriers, the pharmaceutical compositions can contain additives (or auxiliary substances) such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, 25 colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs. Furthermore, in addition to at least one compound of the formula I and/or 30 its physiologically tolerable salts and/or its prodrugs, they can also contain one or more other therapeutically or prophylactically active ingredients.

The compounds of the formula I are antagonists of the vitronectin receptor and inhibitors of cell adhesion. They have, for example, the ability to inhibit the binding of osteoclasts to the bone surface and thereby inhibit bone resorption by osteoclasts.

The action of the compounds of the formula I can be demonstrated, for example, in

- 5 an assay in which the inhibition of the binding of the isolated vitronectin receptor or of cells which contain the vitronectin receptor to a ligand of the vitronectin receptor is determined. Details of such an assay are given below. As vitronectin receptor antagonists, the compounds of the formula I and their physiologically tolerable salts and their prodrugs are generally suitable for the therapy and prophylaxis of diseases
10 which are based on the interaction between vitronectin receptors and their ligands in cell-cell interaction processes or cell-matrix interaction processes, or which can be influenced by an inhibition of interactions of this type, or for the prevention, alleviation or cure of which an inhibition of interactions of this type is desired. As explained at the beginning, such interactions play a part, for example, in bone resorption, in
15 angiogenesis or in the proliferation of cells of the vascular smooth musculature. The compounds of the formula I and their physiologically tolerable salts and their prodrugs are therefore suitable, for example, for the prevention, alleviation or cure of diseases which are caused at least partially by an undesired extent of bone resorption, angiogenesis or proliferation of cells of the vascular smooth musculature.

20

- Bone diseases for whose treatment and prevention the compounds of the formula I according to the invention can be employed are especially osteoporosis, hypercalcemia, osteopenia, for example caused by metastases, dental disorders, hyperparathyroidism, periarticular erosions in rheumatoid arthritis and Paget's
25 disease. In addition, the compounds of the formula I can be used for the alleviation, avoidance or therapy of bone disorders which are caused by a glucocorticoid, steroid or corticosteroid therapy or by a lack of sex hormone(s). All these disorders are characterized by bone loss which is based on the inequilibrium between bone formation and bone destruction and which can be favorably influenced by the
30 inhibition of bone resorption by osteoclasts. The compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs can also favorably be used as inhibitor of bone resorption, for example in the therapy or prophylaxis of

osteoporosis, in combination with conventional osteoporosis treatments, for example in combination with agents like bisphosphonates, estrogens, estrogen/progesterone, estrogen agonists/antagonists, calcitonin, vitamin D analogues, parathyroid hormone, growth hormone secretagogues, or sodium fluoride. Administration of the compounds
5 of the formula I and/or their physiologically tolerable salts and/or their prodrugs and of other active ingredients effective in the treatment or prophylaxis of osteoporosis like those listed before can take place simultaneously or sequentially, in any order, and jointly or separately. For use in such a combination treatment or prophylaxis the compounds of the formula I and/or their physiologically tolerable salts and/or their
10 prodrugs and one or more other active ingredients like those listed before can together be present in a single pharmaceutical composition, for example tablets, capsules or granules, or can be present in two or more separate pharmaceutical compositions which can be contained in a single package or in two or more separate packages. The use of the compounds of the formula I and/or their physiologically
15 tolerable salts and/or their prodrugs in such a combination therapy or prophylaxis and their use in the production of pharmaceuticals for such a combination therapy or prophylaxis are also subjects of the present invention. The invention furthermore relates to pharmaceutical compositions which comprise efficacious amounts of at least one compound of the formula I and/or its physiologically tolerable salts and/or
20 its prodrugs together with at least one other active ingredient effective in the treatment or prophylaxis of osteoporosis or in the inhibition of bone resorption like those listed before, together with a customary pharmaceutically acceptable carrier. The above explanations on pharmaceutical compositions correspondingly apply to such pharmaceutical combination compositions.

25

Apart from use as inhibitors of bone resorption by osteoclasts, the compounds of the formula I and their physiologically tolerable salts and their prodrugs can be used, for example, as inhibitors of tumor growth and tumor metastasis, as antiinflammatories, for the therapy or prophylaxis of rheumatoid arthritis, for the therapy of psoriasis, for
30 the therapy or prophylaxis of cardiovascular disorders such as arteriosclerosis or restenoses, for the therapy or prophylaxis of nephropathies or retinopathies such as, for example, diabetic retinopathy. As inhibitors of tumor growth or tumor metastasis

the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs can also favorably be used in combination with conventional cancer therapy. Examples of conventional cancer therapy are given in Bertino (Editor), Encyclopedia of Cancer, Academic Press, 1997 which is incorporated herein by

5 reference. All the above statements relating to the use of the compounds of formula I in combination with conventional osteoporosis therapy like, for example, possible modes of administration and pharmaceutical combination compositions, correspondingly apply to the use of the compounds of formula I in combination with conventional cancer therapy.

10

When using the compounds of the formula I, the dose can vary within wide limits and, as is customary, is to be suited to the individual conditions in each individual case. It depends, for example, on the compound employed, on the nature and severity of the disease to be treated, or on whether an acute or chronic condition is treated or

15 whether prophylaxis is carried out. In the case of oral administration, the daily dose is in general from about 0.01 to about 100 mg/kg, preferably from about 0.1 to about 50 mg/kg, in particular from about 0.1 to about 5 mg/kg, to achieve effective results in an adult weighing about 75 kg (in each case in mg per kg of body weight). Also in the case of intravenous administration the daily dose is in general from about 0.01 to
20 about 100 mg/kg, preferably from about 0.05 to about 10 mg/kg (in each case in mg per kg of body weight). The daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behavior it may be necessary to deviate upwards or downwards from the daily dose indicated.

25

Apart from use as pharmaceutical active ingredients, the compounds of the formula I can also be used as vehicles or carriers of other active ingredients in order to transport the active ingredient specifically to the site of action (= drug targeting; see, for example, Targeted Drug Delivery, R. C. Juliano, Handbook of Experimental
30 Pharmacology, Vol. 100, Ed. Born, G. V. R. et al., Springer Verlag which is incorporated herein by reference). The active ingredients to be transported are in particular those which can be used for the treatment of the abovementioned


diseases.

The compounds of the formula I and their salts can furthermore be employed for diagnostic purposes, for example in in vitro diagnoses, and as auxiliaries in
 5 biochemical investigations in which blocking of the vitronectin receptor or influencing of cell-cell or cell-matrix interactions is desired. They can furthermore be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional
 10 groups.

Examples

15 Example 1

(2S)-2-Benzylloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid



20

a) 4-([1,8]Naphthyridin-2-yl)-piperidine-1-carboxylic acid tert-butyl ester

3.14 g of 1-tert-butoxycarbonyl-4-acetyl-piperidine and 1.83 g of 2-amino-3-formyl-pyridine were refluxed with 0.25 g of L-proline in n-butanol for 72 hours. After
 25 removing the solvent in vacuo the residue was combined with the residue obtained in an identical reaction and chromatographed on silica gel with ethyl acetate/n-heptane (1:1) to give 1.08 g of the title compound.

b) 4-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-piperidine-1-carboxylic acid tert-butyl ester

0.52 g of the compound of step a) were dissolved in 25 ml of ethyl acetate, and 0.11

5 g of 10 % palladium on charcoal were added under an inert gas atmosphere.

Hydrogenation was performed with this mixture under stirring at ambient temperature until thin layer chromatography did no more show the starting material. The catalyst was removed carefully and washed twice with ethyl acetate. The combined solutions were filtered again and the solvents removed in vacuo. Yield: 0.46 g.

10

c) 7-(Piperidin-4-yl)-1,2,3,4-tetrahydro-[1,8]naphthyridine

0.157 g of the compound of step b) were dissolved in 5 ml of methylene chloride, and

1 ml of trifluoroacetic acid was added under stirring. Stirring was continued for 2.5

15 hours at room temperature. After removal of the solvents in vacuo the oily residue was triturated with diethyl ether. Yield: 0.145 g of a colourless amorphous solid.

d) (2S)-2-Benzylloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

20

0.44 g of the compound of step c) were dissolved in 5 ml of anhydrous dimethylformamide. 0.7 ml of N,N-diisopropylethylamine were added together with 0.58 g of (S)-2-benzylloxycarbonylamino-3-(6-chloro-purin-9-yl)-propionic acid tert-butyl ester, and the mixture was stirred at ambient temperature overnight. Thin layer

25 chromatographic control exhibited only incomplete reaction. Stirring was therefore continued for 6 hours at 40 °C until the reaction was complete. The solvent was removed in vacuo and the residue was dissolved in dichloromethane and washed twice with water. The organic phase was dried with anhydrous magnesium sulfate and, after filtration, concentrated in vacuo. The raw material was chromatographed 30 on silica gel with ethyl acetate and ethyl acetate/methanol (1:10). Yield: 224 mg.

The (2S)-2-benzyloxycarbonylamino-3-(6-chloro-purin-9-yl)-propionic acid tert-butyl ester can be prepared from 6-chloropurine and N-benzyloxycarbonyl-L-serine tert-butyl ester in the presence of triphenylphosphine and diethyl azodicarboxylate according to the procedure described in EP-A-853084 which is incorporated herein

5 by reference.


e) (2S)-2-Benzylcarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid

10 219 mg of the compound of step d) were dissolved in 12 ml of dichloromethane and 2 ml trifluoroacetic acid were added under stirring at ambient temperature. After 6 hours the reaction was complete. The solvents were removed in vacuo. The residue was mixed with toluene and this mixture was again evaporated. The resulting resin was triturated with diethylether. After filtration 210 mg of a faint yellow solid were
15 isolated. MS (ES⁺): m/e = 557.2 (M+H)⁺.

Example 2

(2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid

20



a) (2S)-2-Amino-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

25

878 mg of the compound of example 1, step d) were dissolved in 50 ml of methanol and 0.4 ml of acetic acid. Under a nitrogen atmosphere 350 mg of 10 % palladium on charcoal were carefully added, and hydrogenation was performed under shaking of

the reaction vessel. After 5 hours the reaction was complete. The solvents were removed after filtration of the catalyst. Yield: 680 mg of a resinous product. MS (ES⁺): m/e = 479.3 (M+H)⁺.

5 b) (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

135 mg of the compound of step a) were dissolved in 2.2 ml of dimethylformamide and a solution of 44.2 mg of benzenesulfonyl chloride in 1.5 ml of dimethylformamide 10 was added. After stirring overnight, the reaction was complete. The solvent was removed in vacuo, the residue was dissolved in dichloromethane and washed with water, a 10 % aqueous solution of sodium bicarbonate and again with water. After drying of the organic phase with anhydrous magnesium sulfate and filtration the solvent was removed in vacuo and the residue was chromatographed on silica gel 15 with ethyl acetate. The fractions containing the title compound were pooled and evaporated. Yield: 38 mg. MS (ES⁺): m/e = 619.2 (M+H)⁺.


c) (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid

20 38 mg of the compound of step b) were dissolved in 1.5 ml of dichloromethane, and 1.5 ml of trifluoroacetic acid were added. After stirring for 5 hours at ambient temperature additional 0.1 ml of trifluoroacetic acid were added and stirring was continued for further 1.5 hours. The solvents were removed in vacuo, the residue 25 was dissolved in acetic acid and again the solvent was removed in vacuo. The remaining resin was triturated with diethylether and the product isolated by filtration. Yield: 29 mg. MS (ES⁺): m/e = 563.1 (M+H)⁺.

Analogously to the procedure described in example 2 the compounds of examples 30 3 to 6 were prepared.

Example 3

(2S)-2-(4-Chlorobenzenesulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid




5

From 135 mg of the compound of example 2, step a) and 52.8 mg of 4-chlorobenzenesulfonyl chloride 45 mg of the title compound were obtained.

MS (ES⁺): m/e = 597.1 and 599.1 (M+H)⁺.

10 Example 4

(2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid




15

From 135 mg of the compound of example 2, step a) and 56.7 mg of naphthalene-1-sulfonyl chloride 74 mg of the title compound were obtained.

MS (ES⁺): m/e = 613.1 (M+H)⁺.

20 Example 5

(2S)-3-(6-(4-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)-propionic acid




From 135 mg of the compound of example 2, step a) and 61.2 mg of 4-trifluoromethylbenzenesulfonyl chloride 11.4 mg of the title compound were obtained.

5 MS (FAB): m/e = 631.1 (M+H)⁺.

Example 6

(2S)-2-(Butane-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-purin-9-yl)-propionic acid

10



From 135 mg of the compound of example 2, step a) and 21 mg of butane-1-sulfonyl chloride 13 mg of the title compound were obtained.

15 MS (ES⁺): m/e = 543.2 (M+H)⁺.

Pharmacological Testing

20 1) Kistrin Binding Assay

The inhibition of the binding of kistrin to human vitronectin receptor (VnR) described below is a test method by which the antagonistic action of the compounds of the

invention on the vitronectin receptor $\alpha_v\beta_3$ can be determined ($\alpha_v\beta_3$ ELISA Test; the test method is abbreviated as "K/VnR" in the listing of the test results).

Purification of kistrin

- 5 Kistrin is purified according to the methods of Dennis et al., as described in Proc. Natl. Acad. Sci. USA 87 (1989) 2471 and Proteins: Structure, Function and Genetics 15 (1993) 312.

Purification of human vitronectin receptor ($\alpha_v\beta_3$)

- 10 Human vitronectin receptor is obtained from the human placenta according to the method of Pytela et al., Methods Enzymol. 144 (1987) 475. Human vitronectin receptor $\alpha_v\beta_3$ can also be obtained from some cell lines (for example from 293 cells, a human embryonic kidney cell line) which are co-transfected with DNA sequences for both subunits α_v and β_3 of the vitronectin receptor. The subunits are extracted
15 with octyl glycoside and then chromatographed through concanavalin A, heparin-Sepharose and S-300.

Monoclonal antibodies

- Murine monoclonal antibodies which are specific for the β_3 subunits of the vitronectin
20 receptor, are prepared according to the method of Newman et al., Blood, 1985, 227, or by a similar process. The rabbit Fab 2 anti-mouse Fc conjugate to horseradish peroxidase (anti-mouse Fc HRP) was obtained from Pel Freeze (Catalog No. 715 305-1).

25 ELISA test

- The ability of substances to inhibit the binding of kistrin to the vitronectin receptor can be determined using an ELISA test. For this purpose, Nunc 96-well microtiter plates are coated with a solution of kistrin (0.002 mg/ml) according to the method of Dennis et al., as described in Proteins: Structure, Function and Genetics 15 (1993) 312. The
30 plates are then washed twice with PBS/0.05 % Tween-20 and blocked by incubating (60 min) with bovine serum albumin (BSA, 0.5 %, RIA grade or better) in buffer solution (Tris-HCl (50 mM), NaCl (100 mM), MgCl₂ (1 mM), CaCl₂ (1 mM), MnCl₂

(1 mM), pH 7). Solutions of known inhibitors and of the test substances are prepared in concentrations from 2×10^{-12} to 2×10^{-6} mol/l in assay buffer (BSA (0.5 %, RIA grade or better); Tris-HCl (50 mM), NaCl (100 mM), MgCl₂ (1 mM), CaCl₂ (1 mM), MnCl₂ (1 mM), pH 7). The blocked plates are emptied, and in each case 0.025 ml of
5 this solution which contains a defined concentration (2×10^{-12} to 2×10^{-6} mol/l) either of a known inhibitor or of a test substance, are added to each well. 0.025 ml of a solution of the vitronectin receptor in assay buffer (0.03 mg/ml) is pipetted into each well of the plate and the plate is incubated at room temperature for 60-180 min on a shaker. In the meantime, a solution (6 ml/plate) of a murine monoclonal antibody
10 specific for the β_3 subunit of the vitronectin receptor is prepared in assay buffer (0.0015 mg/ml). A second rabbit antibody (0.001 ml of stock solution/6 ml of the murine monoclonal anti- β_3 antibody solution) which is an anti-mouse Fc HRP antibody conjugate is added to this solution, and this mixture of murine anti- β_3 antibody and rabbit anti-mouse Fc HRP antibody conjugate is incubated during the
15 time of the receptor-inhibitor incubation. The test plates are washed four times with PBS solution which contains 0.05 % Tween-20, and in each case 0.05 ml/well of the antibody mixture is pipetted into each well of the plate and incubated for 60-180 min. The plate is washed four times with PBS/0.05 % Tween-20 and then developed with
20 0.05 ml/well of a PBS solution which contains 0.67 mg/ml of o-phenylenediamine and 0.012 % of H₂O₂. Alternatively to this, o-phenylenediamine can be employed in a buffer (pH 5) which contains Na₃PO₄ and citric acid. The color development is stopped using 1 N H₂SO₄ (0.05 ml/well). The absorption for each well is measured at 492-405 nm and the data are evaluated by standard methods.

25 2) Vitronectin/293 Cell Test

In this test the inhibition of binding of 293 cells to human vitronectin (Vn) by the compounds of the invention is determined (the test method is abbreviated as Vn/293 cell test in the listing of the test results).

30

Purification of human vitronectin

Human vitronectin was isolated from human plasma and purified by affinity

chromatography according to the method of Yatohgo et al., Cell Structure and Function 23 (1988) 281.

Cell test

5 293 cells, a human embryonic kidney cell line, which were cotransfected with DNA sequences for the α_v and β_3 subunits of the vitronectin receptor $\alpha_v\beta_3$, were selected for a high rate of expression ($> 500,000 \alpha_v\beta_3$ receptors/cell) according to the FACS method. The selected cells were cultured and sorted again by means of FACS in order to obtain a stable cell line (15 D) with expression rates $> 1,000,000$ copies of
10 $\alpha_v\beta_3$ per cell.

A Linbro 96-well tissue culture plate with a flat bottom was coated overnight at 4 °C with human vitronectin (0.01 mg/ml, 0.05 ml/well) in phosphate-buffered saline solution (PBS) and then blocked with 0.5 % strength BSA (bovine serum albumin).

15 Solutions of the test substances from 10^{-10} mol/l to 2×10^{-3} mol/l in glucose-containing DMEM medium were prepared and 0.05 ml/well of the solution were added to the plate in each case. The cells which expressed high levels of $\alpha_v\beta_3$ (for example 15 D) were suspended in glucose-containing DMEM medium and the suspension was adjusted to a content of 25,000 cells/0.05 ml of medium. 0.05 ml of
20 this cell suspension was added to each well and the plate was incubated at 37 °C for 90 min. The plate was washed 3 times with warm PBS in order to remove unbound cells. The bound cells were lysed in citrate buffer (25 mM, pH 5.0) which contained 0.25 % Triton X-100. The hexoseamidase substrate p-nitrophenyl-N-acetyl- β -D-glucosaminide was then added and the plate was incubated at 37 °C for 90 min. The
25 reaction was stopped with a glycine (50 mM)/EDTA (5 mM) buffer (pH 10.4) and the absorption of each well was measured at 405 to 650 nm. The data were analyzed according to standard methods.

3) Pit Assay

30

The inhibition of bone resorption by the compounds of the invention can be determined, for example, with the aid of an osteoclast resorption test ("Pit Assay"),

for example analogously to WO-A-95/32710 which is incorporated herein by reference.


The following test results (inhibitory concentrations IC₅₀) were obtained.

5

| Compound | K/VnR | Vn/293 cell test | Pit Assay |
|-----------|-----------------------|-----------------------|-----------------------|
| | IC ₅₀ (nM) | IC ₅₀ (nM) | IC ₅₀ (nM) |
| Example 1 | 10 | 78 | |
| Example 2 | 4.8 | 23 | |
| Example 3 | 5.1 | 15 | 0.3 |
| Example 4 | 6.4 | 24 | < 10 |
| Example 5 | 5 | 22 | |
| Example 6 | 18 | 115 | |

Patent claims

1. A compound of the formula I,



5

in which

G is a residue of the formula II

10 $-(CR^1R^2)_n-A-(CR^1R^2)_m-(CR^1R^3)_l-(CR^1R^2)_q-R^4$ II

A is a direct bond, $-C(O)NR^5-$, $-NR^5C(O)-$, $-C(O)-$, $-NR^5-$, $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, (C_2-C_4) -alkynediyl, (C_2-C_4) -alkenediyl, (C_5-C_{14}) -arylene where in the arylene residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms from 15 the series consisting of nitrogen, oxygen and sulfur, or a divalent residue of a 3-membered to 7-membered saturated or unsaturated ring which can contain one or two ring heteroatoms from the series consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by residues from the series consisting of $=O$, $=S$ and R^3 ;

20

B is (C_1-C_{18}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl, (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C_1-C_6) -alkoxy, (C_1-C_6) -alkoxy- (C_1-C_6) -alkyl-, (C_1-C_6) -alkoxycarbonyl-, (C_1-C_6) -alkylcarbonyl-, (C_5-C_{14}) -arylcarbonyl-, (C_1-C_6) -alkylaminocarbonyl-, (C_1-C_6) -alkoxy- (C_1-C_6) -alkoxy-, (C_5-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyl-, (C_1-C_6) -alkanoylamino-, (C_1-C_6) -

alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, aminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues B are independent of one another and can be identical or different;

5

X is hydrogen, NR⁶R^{6'}, fluorine, chlorine, bromine, OR⁶, SR⁶, hydroxy-(C₁-C₆)-alkyl-NH-, (hydroxy-(C₁-C₆)-alkyl)₂N-, amino-(C₁-C₆)-alkyl-NH-, (amino-(C₁-C₆)-alkyl)₂N-, hydroxy-(C₁-C₆)-alkyl-O-, hydroxy-(C₁-C₆)-alkyl-S- or -NH-C(O)-R⁶;

10 Y is R⁶, fluorine, chlorine, bromine, cyano, NR⁶R^{6'}, OR⁶, SR⁶ or hydroxy-(C₁-C₆)-alkyl-NH-;

Z is N or CH;

15 R¹ and R² are hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶-S(O)_p-R⁷, R⁶S(O)₂NHR⁷, R⁶OC(O)NHR⁷ or R⁶R^{6'}N-R⁷, where all residues R¹ and R² are independent of one another and can be identical or different;

20

R³ is hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶R^{6'}N-R⁷, R⁶C(O)-O-R⁷, R⁶C(O)R⁷, R⁶OC(O)R⁷, R⁶N(R^{6'})C(O)OR⁷, R⁶S(O)_pN(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷,

25 R⁶C(O)N(R⁵)R⁷, R⁶N(R^{6'})C(O)N(R⁵)R⁷, R⁶N(R^{6'})S(O)_pN(R⁵)R⁷, R⁶S(O)_pR⁷, R⁶SC(O)N(R⁵)R⁷, R⁶N(R^{6'})C(O)R⁷ or R⁶N(R^{6'})S(O)_pR⁷, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by R⁶, fluorine, chlorine, bromine, cyano, trifluoromethyl, R⁶R^{6'}NR⁷, nitro, R⁶OC(O)R⁷, R⁶C(O)R⁷, R⁶N(R^{6'})C(O)R⁷,

30 R⁶N(R^{6'})S(O)_pR⁷ or R⁶-O-R⁷, and where all residues R³ are independent of one another and can be identical or different;

R^4 is $-C(O)R^8$, $-C(S)R^8$, $-S(O)_pR^8$, $-P(O)R^8R^{8'}$ or a residue of a 4-membered to 8-membered saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms from the series consisting of nitrogen, oxygen and sulfur;

5

R^5 is hydrogen, (C_1-C_{10}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14}) -aryl or (C_5-C_{14}) -aryl-(C_1-C_8)-alkyl-, where all residues R^5 are independent of one another and can be identical or different;

- 10 R^6 and $R^{6'}$ are hydrogen, (C_1-C_{18}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl-(C_1-C_8)-alkyl-, (C_5-C_{14}) -heteroaryl or (C_5-C_{14}) -heteroaryl-(C_1-C_8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro,
- 15 hydroxycarbonyl-, (C_1-C_6) -alkyl, (C_1-C_6) -alkoxy, (C_1-C_6) -alkoxy-(C_1-C_6)-alkyl-, (C_1-C_6) -alkoxycarbonyl-, (C_1-C_6) -alkylcarbonyl-, (C_1-C_6) -alkylaminocarbonyl-, (C_1-C_6) -alkoxy-(C_1-C_6)-alkoxy-, (C_5-C_{14}) -arylcarbonyl-, (C_5-C_{14}) -aryl-(C_1-C_8)-alkylcarbonyl-, (C_1-C_6) -alkanoylamino-, (C_5-C_{14}) -arylsulfonylamino-, (C_1-C_6) -alkylsulfonylamino-, (C_1-C_6) -alkylamino-, di-((C_1-C_6)-alkyl)amino-, (C_1-C_6) -alkylsulfonyl-, (C_1-C_6) -alkylaminosulfonyl-, (C_5-C_{14}) -arylamino-alkylsulfonyl-, (C_5-C_{14}) -aryl-(C_1-C_8)-alkylaminosulfonyl, (C_5-C_{14}) -arylsulfonyl-, (C_5-C_{14}) -aryl-(C_1-C_8)-alkylsulfonyl, (C_5-C_{14}) -aryl and (C_5-C_{14}) -heteroaryl, and where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;
- 20 25 R^7 is (C_1-C_4) -alkanediyil or a direct bond, where all residues R^7 are independent of one another and can be identical or different;

- R^8 and $R^{8'}$ are hydroxy, (C_1-C_8) -alkoxy, (C_5-C_{14}) -aryl-(C_1-C_8)-alkoxy-, (C_5-C_{14}) -aryloxy, (C_1-C_8) -alkylcarbonyloxy-(C_1-C_4)-alkoxy-, (C_5-C_{14}) -aryl-(C_1-C_8)-alkylcarbonyloxy-(C_1-C_8)-alkoxy-, $NR^6R^{6'}$, (di-((C_1-C_8)-alkyl)amino)carbonylmethoxy-, (di-((C_5-C_{14})-aryl-(C_1-C_8)-alkyl)-amino)carbonylmethoxy-, (C_5-C_{14}) -arylamino-, the residue of an amino acid, $N-((C_1-C_4)$ -alkyl)-piperidin-4-yloxy-, 2-methylsulfonylethoxy-

, 1,3-thiazol-2-ylmethoxy-, 3-pyridylmethoxy-, 2-(di-((C₁-C₄)-alkyl)amino)-ethoxy or the residue Q⁻ (CH₃)₃N⁺-CH₂-CH₂-O- in which Q⁻ is a physiologically tolerable anion, where all residues R⁸ and R^{8'} are independent of one another and can be identical or different;

5

n is zero, one, two, three, four or five;

m is zero, one, two, three, four or five;

i is zero or one;

q is zero, one or two;

10 r is zero, one or two;

s is zero, one, two or three;

t is zero, one, two, three, four, five, six, seven or eight;

p is zero, one or two, where all numbers p are independent of one another and can be identical or different;

15

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

where, instead of the purine structure shown in formula I, also a 3-deazapurine 20 structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present.

2. A compound of the formula I as claimed in claim 1, in which

25 G is a residue of the formula II



A is a direct bond, -C(O)NR⁵-, -NR⁵C(O)-, -C(O)-, -NR⁵-, -O-, -S-, -S(O)-, -S(O)₂-, (C₂-C₄)-alkynediyl, (C₂-C₄)-alkenediyl, (C₅-C₁₄)-arylene where in the arylene residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur, or a divalent residue of a 3-

membered to 7-membered saturated or unsaturated ring which can contain one or two ring heteroatoms from the series consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by residues from the series consisting of =O, =S and R³;

5

B is (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkylcarbonyl-, (C₅-C₁₄)-

10 arylcarbonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl- (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues B are independent of one another and can be identical or different;

15

X is hydrogen, NH₂, -NH-C(O)-R⁶ or OH;

Y is hydrogen;

20 Z is N;

R¹ and R² independently of one another are hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-,

25 R⁶-O-R⁷, R⁶S(O)₂NHR⁷, R⁶OC(O)NHR⁷ or R⁶R^{6'}N-R⁷, where all residues R¹ and R² are independent of one another and can be identical or different;

R³ is hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶R^{6'}N-R⁷, R⁶C(O)-O-R⁷, R⁶C(O)R⁷, R⁶OC(O)R⁷, R⁶N(R^{6'})C(O)OR⁷, R⁶S(O)_pN(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷, R⁶C(O)N(R⁵)R⁷, R⁶N(R^{6'})C(O)N(R⁵)R⁷, R⁶N(R^{6'})S(O)_pN(R⁵)R⁷, R⁶S(O)_pR⁷,

$R^6SC(O)N(R^5)R^7$, $R^6N(R^{6'})C(O)R^7$ or $R^6N(R^{6'})S(O)_pR^7$, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl and heteroaryl can be monosubstituted or polysubstituted by R^6 , fluorine, chlorine, bromine, cyano, trifluoromethyl, $R^6R^{6'}NR^7$, nitro, $R^6OC(O)R^7$, $R^6C(O)R^7$, $R^6N(R^{6'})C(O)R^7$,

- 5 $R^6N(R^{6'})S(O)_pR^7$ or R^6-O-R^7 , and where all residues R^3 are independent of one another and can be identical or different;

R^4 is $-C(O)R^8$ or $-P(O)R^8R^{8'}$;

- 10 R^5 is hydrogen, (C_1-C_{10})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl- or (C_5-C_{14})-aryl-(C_1-C_8)-alkyl-, where all residues R^5 are independent of one another and can be identical or different;

- 15 R^6 and $R^{6'}$ are hydrogen, (C_1-C_{12})-alkyl, (C_3-C_{14})-cycloalkyl, (C_3-C_{14})-cycloalkyl-(C_1-C_8)-alkyl-, (C_5-C_{14})-aryl, (C_5-C_{14})-aryl-(C_1-C_8)-alkyl-, (C_5-C_{14})-heteroaryl or (C_5-C_{14})-heteroaryl-(C_1-C_8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy, (C_1-C_6)-alkoxy-(C_1-C_6)-alkyl-, (C_5-C_{14})-arylcarbonyl-, (C_5-C_{14})-aryl-(C_1-C_6)-arylcarbonyl-, (C_1-C_6)-alkanoylamino-, (C_5-C_{14})-arylsulfonylamino-, (C_1-C_6)-alkylsulfonylamino-, (C_1-C_6)-alkylamino-, di-((C_1-C_6)-alkyl)amino-, (C_1-C_6)-alkylsulfonyl-, (C_5-C_{14})-aryl and (C_5-C_{14})-heteroaryl, and where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

25

R^7 is (C_1-C_4)-alkanediyl or a direct bond, where all residues R^7 are independent of one another and can be identical or different;

- 30 R^8 and $R^{8'}$ are hydroxy, (C_1-C_8)-alkoxy, (C_5-C_{14})-aryl-(C_1-C_8)-alkoxy-, (C_1-C_8)-alkylcarbonyloxy-(C_1-C_4)-alkoxy- or $NR^6R^{6'}$ where all residues R^8 and $R^{8'}$ are independent of one another and can be identical or different;

n is zero, one, two, three, four or five;

m is zero, one, two, three, four or five;

i is zero or one;

5 q is zero, one or two;

r is zero, one or two;

s is zero, one, two or three;

t is zero, one, two, three, four, five, six, seven or eight;

p is zero, one or two, where all numbers p are independent of one another and can

10 be identical or different;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs.

15 3. A compound of the formula I as claimed in claims 1 and/or 2, in which

G is a residue of the formula II



20

A is a direct bond, -C(O)NR⁵-, -NR⁵C(O)-, -C(O)-, -NR⁵- or (C₅-C₁₄)-arylene where in the arylene residue one or two ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur;

25 B is (C₁-C₆)-alkyl, chlorine, hydroxy, cyano, trifluoromethyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylamino- or di-((C₁-C₆)-alkyl)amino-, where all residues B are independent of one another and can be identical or different;

30 X is hydrogen;

Y is hydrogen;

Z is N;

R¹ and R² are hydrogen, (C₁-C₄)-alkyl, R⁶S(O)₂NHR⁷ or R⁶OC(O)NHR⁷, where all residues R¹ and R² are independent of one another and can be identical or different;

R³ is hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₆)-alkyl-, R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl and heteroaryl can be monosubstituted or polysubstituted by R⁶, fluorine, chlorine, trifluoromethyl, R⁶C(O)R⁷ or R⁶-O-R⁷;

R⁴ is -C(O)R⁸;

15

R⁵ is hydrogen or (C₁-C₄)-alkyl, where all residues R⁵ are independent of one another and can be identical or different;

R⁶ and R^{6'} are hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl, and where all residues R⁶ and R^{6'} are independent of one another and can be identical or different;

R⁷ is (C₁-C₂)-alkanediyl or a direct bond, where all residues R⁷ are independent of one another and can be identical or different;

30

R⁸ is hydroxy or (C₁-C₆)-alkoxy;

n is zero, one, two, three, four or five;

m is zero or one;

i is zero or one;

q is zero or one;

5 r is zero or one;

s is zero, one or two;

t is zero, one, two, three or four;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their

10 physiologically tolerable salts and their prodrugs.

4. A compound of the formula I as claimed in one or more of claims 1 to 3, in which

G is a residue of the formula II

15



A is a direct bond;

20 B is (C₁-C₆)-alkyl or hydroxy, where all residues B are independent of one another and can be identical or different;

X is hydrogen;

25 Y is hydrogen;

Z is N;

R¹ and R² are hydrogen, (C₁-C₄)-alkyl, R⁶S(O)₂NHR⁷ or R⁶OC(O)NHR⁷, where all
30 residues R¹ and R² are independent of one another and can be identical or different;

R³ is hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₆)-alkyl-, R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl and heteroaryl can be monosubstituted or polysubstituted by R⁶, fluorine, chlorine, trifluoromethyl, R⁶C(O)R⁷ or R⁶-O-R⁷;

R⁴ is -C(O)R⁸;

10 R⁵ is hydrogen or (C₁-C₄)-alkyl;

R⁶ and R^{6'} are hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be

15 substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl, and where all residues R⁶ and R^{6'} are independent of one another and can be identical or different;

20

R⁷ is a direct bond;

R⁸ is hydroxy or (C₁-C₄)-alkoxy;

25 n is zero, one or two;

m is zero or one;

i is zero or one;

q is zero or one;

r is zero or one;

30 s is zero, one or two;

t is zero;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs.

5. A compound of the formula I as claimed in one or more of claims 1 to 4, which is a

5

G is a residue of the formula II



10 A is a direct bond;

X is hydrogen;

Y is hydrogen;

15

Z is N;

R¹ and R² are hydrogen or (C₁-C₂)-alkyl, where all residues R¹ and R² are independent of one another and can be identical or different;

20

R³ is R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or R⁶C(O)N(R⁵)R⁷;

R⁴ is -C(O)R⁸;

25 R⁵ is hydrogen or (C₁-C₂)-alkyl;

R⁶ and R^{6'} are hydrogen, (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-

C_{14})-heteroaryl, and where the residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

R^7 is a direct bond;

5

R^8 is hydroxy or (C_1 - C_4)-alkoxy;

n is zero, one or two;

m is zero or one;

10 i is zero or one;

q is zero or one;

r is zero;

s is zero;

t is zero;

15

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs

6. A compound of the formula I as claimed in one or more of claims 1 to 5, which is a

20

G is a residue of the formula II



25 A is a direct bond;

X is hydrogen;

Y is hydrogen;

30

Z is N;

R¹ and R² are hydrogen;

R³ is R⁶S(O)₂N(R⁵)R⁷ or R⁶OC(O)N(R⁵)R⁷;

5 R⁴ is -C(O)R⁸;

R⁵ is hydrogen;

10 R⁶ is (C₁-C₁₂)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

15

R⁷ is a direct bond;

R⁸ is hydroxy or (C₁-C₄)-alkoxy;

20 n is one;

m is zero;

i is one;

q is zero;

r is zero;

25 s is zero;


t is zero;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs

30

7. A process for the preparation of a compound as claimed in one or more of claims 1 to 6, comprising reacting a compound of the formula VI with a compound of the

formula VIIa or with a compound of the formula VIIb



- 5 wherein L^1 is a leaving group and B, G, X, Y, r, s and t are defined as in claims 1 to 6 but wherein functional groups can also be present in the form of precursor groups or in protected form.
8. A pharmaceutical composition, comprising at least one compound of the formula I
10 as claimed in one or more of claims 1 to 6 and/or its physiologically tolerable salts and/or its prodrugs and a pharmaceutically acceptable carrier.
9. A compound of the formula I as claimed in one or more of claims 1 to 6 and/or its physiologically tolerable salts and/or its prodrugs for use as a vitronectin receptor
15 antagonist.
10. A compound of the formula I as claimed in one or more of claims 1 to 6 and/or its physiologically tolerable salts and/or its prodrugs for use as an inhibitor of bone resorption, for the therapy or prophylaxis of osteoporosis, as an inhibitor of tumor
20 growth or tumor metastasis, as an antiinflammatory, or for the therapy or prophylaxis of cardiovascular disorders, restenoses, arteriosclerosis, nephropathies, retinopathies, psoriasis or rheumatoid arthritis.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05920

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D473/34 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | EP 0 853 084 A (HOECHST AG ;GENENTECH INC (US)) 15 July 1998 (1998-07-15) cited in the application examples 19,26,28,29 --- | 1-10 |
| Y | WO 98 31359 A (DUGGAN MARK E ;MERCK & CO INC (US)) 23 July 1998 (1998-07-23) claims 4-13 --- | 1-10 |
| Y | WO 98 18461 A (HOFFMAN WILLIAM F ;DUGGAN MARK E (US); IHLE NATHAN C (US); MERCK &) 7 May 1998 (1998-05-07) cited in the application * page 38,page 48 * --- | 1-10 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 August 2000

Date of mailing of the international search report

23/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05920

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | WO 95 32710 A (MERCK & CO INC ;HARTMAN GEORGE D (US); DUGGAN MARK E (US); IHLE NA) 7 December 1995 (1995-12-07) cited in the application * compounds 32-6,33-3,34-8,34-9 * --- | 1-10 |
| A | WO 98 08840 A (HOFFMAN WILLIAM F ;HUTCHINSON JOHN H (US); MEISSNER ROBERT S (US);) 5 March 1998 (1998-03-05) cited in the application * pages 90,115,134 * --- | 1-10 |
| A | WO 99 32457 A (CUTHBERTSON ROBERT ANDREW ;KNOLLE JOCHEN (DE); BREIPOHL GERHARD (D) 1 July 1999 (1999-07-01) cited in the application abstract ---- | 1-10 |
| A,P | WO 99 37621 A (CUTHBERTSON ROBERT ANDREW ;SCHEUNEMANN KARLHEINZ (DE); KNOLLE JOCH) 29 July 1999 (1999-07-29) abstract ----- | 1-10 |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05920

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|--|---|------------------|--|--|--|--|
| EP 0853084 | A | 15-07-1998 | | DE 19653646 A AU 4846697 A BR 9706387 A CA 2225366 A CN 1193623 A CZ 9704114 A HU 9702507 A JP 10182645 A NO 975977 A PL 323969 A | | 25-06-1998 25-06-1998 14-03-2000 20-06-1998 23-09-1998 15-07-1998 28-05-1999 07-07-1998 22-06-1998 22-06-1998 |
| WO 9831359 | A | 23-07-1998 | | AU 6023198 A EP 1007026 A | | 07-08-1998 14-06-2000 |
| WO 9818461 | A | 07-05-1998 | | AU 717283 B AU 5088498 A EP 0946164 A US 5919792 A | | 23-03-2000 22-05-1998 06-10-1999 06-07-1999 |
| WO 9532710 | A | 07-12-1995 | | AU 701776 B AU 2586895 A CA 2190870 A EP 0760658 A JP 10501222 T US 5929120 A US 5741796 A | | 04-02-1999 21-12-1995 07-12-1995 12-03-1997 03-02-1998 27-07-1999 21-04-1998 |
| WO 9808840 | A | 05-03-1998 | | AU 4086597 A EP 0934305 A US 5981546 A | | 19-03-1998 11-08-1999 09-11-1999 |
| WO 9932457 | A | 01-07-1999 | | EP 0933367 A AU 2270099 A | | 04-08-1999 12-07-1999 |
| WO 9937621 | A | 29-07-1999 | | AU 2518199 A | | 09-08-1999 |

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18384 A1

(51) International Patent Classification⁷: **C07D 473/40**, 473/34, 239/42, 239/48, 401/12, 519/00 // (C07D 519/00, 473/00, 471/00)

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA.

(21) International Application Number: PCT/EP01/09985

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 29 August 2001 (29.08.2001)

Declaration under Rule 4.17:
of inventorship (Rule 4.17(iv)) for US only

(25) Filing Language: English

Published:

(26) Publication Language: English

*with international search report
before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(30) Priority Data:
100 42 655.7 31 August 2000 (31.08.2000) DE

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): **AVEN-TIS PHARMA DEUTSCHLAND GMBH** [DE/DE]; Brüningstrasse 50, 95929 Frankfurt am Main (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PEYMAN, Anuschirwan** [DE/DE]; Zeilsheimer Strasse 46, 65779 Kelkheim (DE). **SCHUBERT, Gerrit** [DE/DE]; Feldbergstrasse 2a, 65779 Kelkheim (DE).

(74) Agent: **ROUSSEAU, Pierrick**; Aventis Pharma S.A., 102, route de Noisy, F 93235 Romainville Cedex (FR).


WO 02/18384 A1

(54) Title: PROCESS FOR THE PREPARATION OF VITRONECTIN RECEPTOR ANTAGONISTS

(57) **Abstract:** The present invention relates to a process for the preparation of vitronectin receptor antagonists of the formula (I) by linkage of a 9 chloropurine of the formula (I) by linkage of a 9 chloropurine of the formula (IV) to a 4 substituted piperidine and comprises an efficient method for the preparation of compounds of the formula (IV).


PROCESS FOR THE PREPARATION OF VITRONECTIN RECEPTOR ANTAGONISTS

The present invention relates to a process for the preparation of vitronectin receptor antagonists of the formula (I) by linkage of a 9-chloropurine of the formula (IV) to a 5 4-substituted piperidine and comprises an efficient method for the preparation of compounds of the formula (IV).



- 10 Inhibitors of cell adhesion and in particular antagonists of the vitronectin receptor are of especial interest in the pharmaceutical industry as they can be used for the treatment of a series of diseases (Hillis et al., Clinical Science 91 (1996) 639; Engleman et al., Ann. Rep. Med. Chem. 31 (1996) 191; Samanen et al., Current Pharm. Design 3 (1997) 545).
- 15 In European patent applications EP 0853084, EP 1065207 (EP 99112636.8) and EP 1065208 (EP 99112637.6), vitronectin receptor antagonists of the formula (I) are described in which V is the radicals of the formulae (II) or (III).

Compounds of the formula (I) in which V is a radical of the formula (II) are designated below as compounds of the formula (I-A). Compounds of the formula (I) in which V is a radical of the formula (III) are designated below as compounds of the formula (I-B).



5

Known processes for the preparation of compounds of the formula (I) are based on the preparation of a suitable 9-substituted purine derivative having a nucleophilically substitutable leaving group in the 6-position, for example of a 6-chloropurine derivative of the formula (IV), which is converted into a compound of the formula (I) in several steps by reaction with a 4-substituted piperidine derivative.


The compounds of the formula (IV) needed are prepared in only low yields by alkylation in the 9-position of the purine structure via a Mitsunobu reaction and require laborious chromatographic purifications (EP 1065207 (EP 99112636.8)). The process is therefore not suitable for syntheses on a relatively large scale.

It is an object of the present invention to find a more efficient process for the synthesis of compounds of the formula (I).

- 5 The object is achieved by a novel process for the preparation of compounds of the formula (I) comprising an efficient method for the synthesis of compounds of the formula (IV) and a process based on this for the preparation of compounds of the formula (I).
- 10 One subject of the invention is thus a process for the preparation of a compound of the formula (IV), which comprises

first reacting the 5-nitropyrimidine of the formula (V) by a method known to the person skilled in the art (see source literature in March, Advanced Organic

- 15 Chemistry, Fourth Edition, John Wiley & Sons, 1992; or Kelley, J. Med. Chem. 33 (1990) 196) with a primary amine of the formula (VI) to give a compound of the formula (VII),




20

the reaction preferably being carried out in a suitable organic solvent, for example ethanol, isopropanol, butanol, DCM, CHCl_3 , THF, diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-butyl ether, acetonitrile, DMF,

DMSO, dioxane, toluene, benzene, EA, or a mixture of two or more of these solvents, preferably in THF, if appropriate with addition of a base such as butyllithium, LDA, sodium hydride, sodium amide, potassium tert-butoxide, CaCO_3 , Cs_2CO_3 , TEA, DIPEA, complex bases (sodium amide- R^{12}ONa , where R^{12} is ($\text{C}_2\text{-C}_6$)-alkyl or 5 $\text{CH}_3\text{CH}_2\text{OCH}_2\text{CH}_2$), it also being possible for an excess of (VI) to serve as base.

The reaction is in general carried out at temperatures from -20 to 150°C, preferably at temperatures from -20 to 100°C.

In a subsequent step, the compound of the formula (VII) is reduced by a process known to the person skilled in the art (March, Advanced Organic Chemistry, Fourth Edition, John Wiley & Sons, 1992; R. C. Larock, Comprehensive Organic Transformations, VCH, Weinheim, 1989) to give a compound of the formula (VIII),




15

for example by catalytic hydrogenation by means of Raney nickel or palladium or by reduction using SnCl_2 . The catalytic hydrogenation is optionally carried out in a suitable organic solvent, such as ethanol, methanol, acetic acid, THF, diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-butyl ether, dioxane, EA or in a mixture of two or more of these solvents, preferably in ethanol or methanol, for example at temperatures from 0 to 100°C and at hydrogen

pressures from 1 to 10 bar. The reaction with SnCl_2 is preferably carried out in a suitable organic solvent such as ethanol, methanol, DCM, CHCl_3 , THF, diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-butyl ether, acetonitrile, DMF, DMSO, N-methylpyrrolidone, dioxane, toluene, benzene, EA or in a mixture of two or more of these solvents, preferably in ethanol, for example at 5 temperatures from 0 to 100°C, preferably from 50 to 100°C.

In a further step, the compound of the formula (VIII) is cyclized by a method known to the person skilled in the art (March, Advanced Organic Chemistry, Fourth Edition, 10 John Wiley & Sons, 1992; or Kelley, J. Med. Chem. 33 (1990) 196) by means of a C₁ unit to give a compound of the formula (IV),



15 where the C₁ unit is, for example, a formic acid derivative, preferably a tri-(C₁-C₄)-alkyl orthoformate, particularly preferably triethyl orthoformate, and where the reaction is optionally carried out in the presence of an acid, such as an alkylsulfonic or arylsulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, an acidic ion exchanger, HCl, preferably ethanesulfonic acid, and where furthermore the
20 reaction is optionally carried out in a suitable organic solvent such as THF, diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-

butyl ether, acetonitrile, DMF, DMSO, NMP, dioxane, toluene, benzene, EA or a mixture of two or more of these solvents.

In the compounds of the formulae (I), (I-A), (I-B), (IV), (VI), (VII) and (VIII),

5

R¹, R², R³, R⁴ independently of one another are hydrogen, fluorine, chlorine, CN, (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶R^{6'}N-R⁷, R⁶C(O)R⁷,

R⁶S(O)₂N(R⁹)R⁷, R⁶OC(O)N(R⁹)R⁷, R⁶C(O)N(R⁵)R⁷, R⁶N(R⁹)C(O)N(R⁹)R⁷,

10 R⁶N(R⁹)S(O)₂N(R⁹)R⁷, R⁶S(O)₂R⁷, R⁶SC(O)N(R⁹)R⁷, R⁶N(R⁹)C(O)R⁷,
R⁶N(R⁹)S(O)₂R⁷, R⁶N(R⁹)R⁷ or a 3-membered to 7-membered, saturated or unsaturated ring which can contain one or two heteroatoms such as nitrogen, sulfur and oxygen and which can be unsubstituted or mono- or disubstituted by =O, =S and R⁸,

15 where alkyl, cycloalkyl and aryl radicals can be mono- or polysubstituted by fluorine, chlorine, bromine, CF₃, CN, R⁶N(R⁹)R⁷, R⁶R^{6'}NR⁷, R⁶C(O)R⁷, R⁶N(R⁹)C(O)R⁷,
R⁶N(R⁹)S(O)₂R⁷, R⁶, R⁶-O-R⁷;

R⁵ is hydroxyl, (C₁-C₈)-alkoxy, (C₅-C₁₄)-aryl-(C₁-C₈)-alkoxy-, (C₁-C₈)-

20 alkylcarbonyloxy-(C₁-C₄)-alkoxy-, (C₃-C₁₄)-cycloalkoxy or (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkoxy-;

R⁶, R^{6'} independently of one another are (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- or a 3-

25 membered to 7-membered, saturated or unsaturated ring which can contain one or two heteroatoms, such as nitrogen, sulfur and oxygen, and is unsubstituted or mono- or disubstituted by =O, =S and R⁸,

- where aryl, cycloalkyl and alkyl radicals can be substituted once, twice or three times by fluorine, chlorine, bromine, cyano, CF₃, nitro, carboxyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₅-C₁₄)-aryl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl, (C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkylaminocarbonyl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, 5 (C₅-C₁₄)-aryl-(C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkanoylamino, (C₅-C₁₄)-arylsulfonylamino, (C₁-C₆)-alkylsulfonylamino, (C₁-C₆)-alkylamino, di-((C₁-C₆)-alkyl)amino, (C₁-C₆)-alkylsulfonyl, (C₁-C₆)-alkylaminosulfonyl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkylaminosulfonyl or (C₅-C₁₄)-aryl-(C₁-C₆)-alkylsulfonyl;
- 10 R⁷ independently of one another is (C₁-C₄)-alkanediyI or a direct bond;
- R⁸ is (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, cyano, CF₃, nitro, carboxyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl, 15 (C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkylaminocarbonyl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkanoylamino, (C₅-C₁₄)-arylsulfonylamino, (C₁-C₆)-alkylsulfonylamino, (C₁-C₆)-alkylamino, di-(C₁-C₆)-alkylamino, (C₁-C₆)-alkylsulfonyl, (C₁-C₆)-alkylaminosulfonyl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkylaminosulfonyl or (C₅-C₁₄)-Aryl-(C₁-C₆)-alkylsulfonyl; and
- 20 R⁹ is hydrogen or (C₁-C₄)-alkyl.

The alkyl radicals occurring in the substituents can be straight-chain or branched, saturated or mono- or polyunsaturated. This also applies if they carry substituents or 25 occur as substituents of other radicals, for example in alkoxy, alkoxycarbonyl or arylalkyl. The same applies to alkanediyI radicals.

Unsaturated alkyl radicals and alkanediyI radicals are, for example, alkenyl, alkenylene, alkynyl and alkynylene radicals. Examples of alkenyl radicals are vinyl, 1-

propenyl, allyl, butenyl, 3-methyl-2-butenyl, examples of alkynyl radicals are ethynyl, 1-propynyl or propargyl. Examples of alkenylene radicals are vinylene or propenylene, examples of alkynylene radicals are ethynylene or propynylene. Alkenylene and alkynylene radicals can be straight-chain or branched.

5

Examples of alkyl radicals are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, decyl, undecyl, dodecyl, tridecyl, hexadecyl, octadecyl, isopropyl, isobutyl, isopentyl, neopentyl, isoheptyl, 3-methylpentyl, 2,3,4-trimethylhexyl, sec-butyl, tert-butyl, tert-pentyl. Preferred alkyl radicals are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl
10 and tert-butyl.

Cycloalkyl radicals can be monocyclic, bicyclic or tricyclic. Monocyclic cycloalkyl radicals are, in particular, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which, however, can also be substituted by, for example, (C₁-C₄)
15 alkyl. 4-Methylcyclohexyl and 2,3-dimethylcyclopentyl may be mentioned as examples of substituted cycloalkyl radicals.

Bicyclic and tricyclic cycloalkyl radicals can be unsubstituted or can be substituted in any desired suitable positions, for example by one or more oxo groups and/or one or
20 more identical or different (C₁-C₄)-alkyl groups, such as methyl or isopropyl groups, preferably methyl groups. The free bond of the bicyclic or tricyclic radical can be situated in any desired position of the molecule; the radical can thus be bonded via a bridgehead atom or an atom in a bridge. The free bond can also be situated in any desired stereochemical position, for example in an exo or an endo position.

25

Examples of parent structures of bicyclic ring systems are norbornane (= bicyclo[2.2.1]heptane), bicyclo[2.2.2]octane and bicyclo[3.2.1]octane. An example of a parent bicyclic system substituted by an oxo group is camphor (= 1,7,7-trimethyl-2-oxobicyclo[2.2.1]heptane). Examples of parent structures of tricyclic systems are
30 twistane (= tricyclo[4.4.0.0^{3,8}]decane, adamantane (= tricyclo[3.3.1.1^{3,7}]decane), noradamantane (= tricyclo[3.3.1.0^{3,7}]nonane), tricyclo[2.2.1.0^{2,6}]heptane,

tricyclo[5.3.2.0^{4,9}]dodecane, tricyclo[5.4.0.0^{2,9}]undecane or tricyclo[5.5.1.0^{3,11}]tridecane. An adamantyl radical can be 1-adamantyl or 2-adamantyl.

- 5 Aryl is, for example, carbocyclic (C₆-C₁₄)-aryl radicals such as phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, preferably phenyl, 1-naphthyl, 2-naphthyl, particularly preferably phenyl. If not stated otherwise, aryl radicals, in particular phenyl radicals, can be mono- or polysubstituted, preferably mono-, di- or trisubstituted, independently of one another by radicals from the group consisting of (C₁-C₈)-alkyl,
10 in particular (C₁-C₄)-alkyl, (C₁-C₈)-alkoxy, in particular (C₁-C₄)-alkoxy, halogen, such as fluorine, chlorine and bromine, nitro, amino, trifluoromethyl, hydroxyl, methylenedioxy, cyano, hydroxycarbonyl, aminocarbonyl, (C₁-C₄)-alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy, tetrazolyl, (R¹⁰O)₂P(O) or (R¹⁰O)₂P(O)-O-, where R¹⁰ = H, (C₁-C₁₀)-alkyl, (C₅-C₁₄)-aryl or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-.
- 15 The same applies to the corresponding arylene radicals.

In monosubstituted phenyl radicals, the substituent can be situated in the 2-position, 3-position or 4-position, the 3-position and 4-position being preferred. If phenyl is disubstituted; the substituents can be in the 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-position.

- 20 Preferably, in disubstituted phenyl radicals the two substituents are arranged in the 3,4-position relative to the site of linkage.

Aryl and arylene groups can furthermore be monocyclic or polycyclic heteroaromatic ring systems, in which 1, 2, 3, 4 or 5 carbon atoms can be replaced by heteroatoms

- 25 from the group consisting of N, O and S, such as 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, β -carbolinyl, or a benzo-fused, cyclopenta-fused, cyclohexa-fused or cyclohepta-fused derivative of these
- 30 radicals such as benzoxazolyl, benzothiazolyl or benzimidazolyl. These heterocycles

can be substituted by the same substituents as the abovementioned carbocyclic aryl systems.

Among these heteroaryl groups and the corresponding heteroarylene groups,
5 monocyclic or bicyclic aromatic ring systems having 1, 2 or 3 heteroatoms from the group consisting of N, O, S, which can be substituted by 1, 2 or 3 substituents from the group consisting of (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, F, Cl, NO₂, NH₂, CF₃, hydroxyl, (C₁-C₄)-alkoxycarbonyl, phenyl, phenoxy, benzyloxy and benzyl, are preferred. Particularly preferred are monocyclic or bicyclic aromatic ring systems
10 having 1, 2 or 3 heteroatoms from the group consisting of N, O, S, which can be substituted by 1 or 2 substituents from the group consisting of (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, phenyl, phenoxy, benzyl and benzyloxy.

Examples of 3-membered, 4-membered, 5-membered, 6-membered and 7-membered, saturated or unsaturated rings which can contain one or two heteroatoms, such as nitrogen, sulfur and oxygen, and are optionally mono- or disubstituted by =O, =S and R⁸, are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, tetrahydropyran, 1,4-dioxacyclohexane, morpholine, piperazine, piperidine,
20 pyrrolidine, dihydroisoxazole, tetrahydroisoxazole, 1,3-dioxolane, 1,2-dithiolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, 2,3-dihydrothiophene, 2,5-dihydrothiophene, 2-imidazoline, 3-imidazoline, 4-imidazoline, 2-oxazoline, 3-oxazoline, 4-oxazoline, 2-thiazoline, 3-thiazoline, 4-thiazoline, thiazolidine, α-thiapyran, α-pyran, γ-pyran.

25

The invention preferably relates to a process for the preparation of compounds of the formula (IV) wherein

R¹, R², R³, R⁴ independently of one another are hydrogen, (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl- (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-

(C₁-C₈)-alkyl-, R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁹)R⁷, R⁶N(R⁹)S(O)₂N(R⁹)R⁷, R⁶OC(O)N(R⁹)R⁷, R⁶C(O)N(R⁹)R⁷, R⁶N(R⁹)R⁷ or a 3-membered to 7-membered, saturated or unsaturated ring which can contain one or two heteroatoms, such as nitrogen, sulfur and oxygen and which can optionally be mono- or disubstituted by

5 =O, =S and R⁸,

where alkyl, cycloalkyl and aryl radicals can be mono- or polysubstituted by fluorine, chlorine, bromine, CF₃, CN and R⁶-O-R⁷;

R⁵ is hydroxyl or (C₁-C₄)-alkoxy;

10

R⁶, R^{6'} independently of one another are (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- or a 3-membered to 7-membered, saturated or unsaturated ring which can contain one or two heteroatoms, such as nitrogen, sulfur and oxygen and which can optionally be

15 mono- or disubstituted by =O, =S and R⁸;

where aryl, cycloalkyl and alkyl radicals can be mono- to trisubstituted by fluorine, chlorine, bromine, cyano, CF₃, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₅-C₁₄)-aryl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl, (C₁-C₆)-alkylcarbonyl;

20 R⁷ independently of one another is (C₁-C₄)-alkylene or a direct bond;

R⁸ is (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, CF₃, (C₁-C₆)-alkoxy or (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-; and

25

R⁹ is hydrogen or (C₁-C₄)-alkyl.

The invention particularly preferably relates to a process for the preparation of compounds of the formula (IV) wherein

R¹, R², R³, R⁴ independently of one another are hydrogen, R⁶S(O)₂N(R⁹)R⁷ or R⁶OC(O)N(R⁹)R⁷;

5

R⁵ is (C₁-C₄)-alkoxy, preferably ethoxy or tert-butoxy;



R⁶ is (C₅-C₁₄)-aryl, preferably 1-naphthyl, or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, preferably benzyl;

10

R⁷ is a direct bond; and

R⁹ is hydrogen.

15 By reaction with compounds of the formula (IX-A) or (IX-B), the compounds of the formula (IV) then yield the compounds of the formula (I-A) or (I-B).



A subject of the invention also is a process for the preparation of the compounds of the formula (I-A), which comprises reacting a compound of the formula (IV) with a compound of the formula (IX-A).

- 5 A subject of the invention furthermore is the use of the compounds of the formula (IV) for the production of pharmaceutical active compounds, which comprises reacting a compound of the formula (IV) with a compound of the formula (IX-A) to give a compound of the formula (I-A), or reacting a compound of the formula (IV) with a compound of the formula (IX-B) to give a compound of the formula (I-B), compounds
10 of the formula (I-B) being excluded in which R¹ and R² are hydrogen, one of the radicals R³ and R⁴ is benzyl-O-C(O)-NH- and the other is hydrogen, and R⁵ is hydroxyl or tert-butoxy.

The compounds of the formula (I-A) and (I-B) are preferably prepared in a single
15 step, if appropriate in a suitable organic solvent, by methods known to the person skilled in the art (see source literature in March, Advanced Organic Chemistry, Fourth Edition, John Wiley & Sons, 1992). Suitable organic solvents are, for example, DCM, CHCl₃, THF, diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-butyl ether, acetonitrile, DMF, DMSO, N-methylpyrrolidone,
20 dioxane, toluene, benzene, EA or mixtures of two or more of these solvents, preferably DMF. The reaction is preferably carried out with addition of a base such as butyllithium, lithium diisopropylamide (LDA), sodium hydride, sodium amide, potassium tert-butoxide, CaCO₃, Cs₂CO₃, triethylamine, diisopropylethylamine, complex bases (sodium amide-R¹²ONa, where R¹² is (C₂-C₆)-alkyl or
25 CH₃CH₂OCH₂CH₂), where, however, an excess of (IX) can also serve as a base. The reaction is particularly preferably carried out in the presence of triethylamine (TEA) or diisopropylethylamine (DIPEA), for example at temperatures from 0 to 150°C, preferably at temperatures from 25 to 120°C, particularly preferably at temperatures from 50 to 100°C. The above-defined preferred embodiments of the

radicals R¹ to R⁹ in the process for the preparation of compounds of the formula (IV) here correspondingly apply.

In contrast to the prior art, the process according to the invention gives good yields in
5 a lower number of process steps and can advantageously be used for syntheses on
a relatively large scale.


A further subject of the present invention relates to a process for the preparation of a compound of the formula (I-A) in which the compound of the formula (V) is reacted
10 with a compound of the formula (VI), the compound of the formula (VII) obtained is reduced to the compound of a formula (VIII), the compound of the formula (VIII) obtained is reacted with a C₁ unit, and the compound of the formula (IV) obtained is reacted with a compound of the formula (IX-A) to give a compound of the formula (I-A), where all above definitions and explanations with respect to the radicals R¹ to
15 R⁹ and the reaction conditions correspondingly apply.

Another subject of the present invention relates to a process for the preparation of a compound of the formula (I-B), in which the compound of the formula (V) is reacted with a compound of the formula (VI), the compound of the formula (VII) obtained is
20 reduced to a compound of the formula (VIII), the compound of the formula (VIII) obtained is reacted with a C₁ unit, and the compound of the formula (IV) obtained is reacted with a compound of the formula (IX-B) to give a compound of the formula (I-B), where all above definitions and explanations with respect to the radicals R¹ to R⁹ and the reaction conditions correspondingly apply.

25

The invention further relates to a process for the preparation of a compound of the formula (IX-A), which comprises

first reacting a compound of the formula (X) with 2-aminopyrimidine (XI) to give a
30 compound of the formula (XII)



where PG is a suitable amino protective group (Greene, Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1999), for example tert-butoxycarbonyl or

- 5 benzyloxycarbonyl, preferably tert-butoxycarbonyl, and L is a nucleophilically substitutable leaving group, for example chlorine, a pentafluorophenoxy, phenoxy, phenylthio, methylthio or 2-pyridylthio group, or a nitrogen heterocycle, for example 1-imidazolyl. L is particularly preferably a pentafluorophenoxy group. The compounds of the formula (XII) are preferably prepared in a manner known to the person skilled
- 10 in the art (March, Advanced Organic Chemistry, Third Edition, John Wiley & Sons, 1985) either from the respective carboxylic acid chlorides (L = Cl) which can in turn be prepared in a manner known per se from the underlying carboxylic acids (L = OH) using, for example, thionyl chloride, or from other activated carboxylic acid derivatives such as from the methyl esters (L = OCH₃) which are obtainable from the
- 15 acids by treating with gaseous HCl in methanol, from the imidazolides (L = 1-imidazolyl) which are obtainable by treating the acids with carbonyldiimidazole (Staab, Angew. Chem. Int. Ed. Engl. 1 (1962) 351-367), or from mixed anhydrides (L = C₂H₅O-C(O)-O or TosO) which are obtainable with Cl-COOOC₂H₅ or tosyl chloride in the presence of triethylamine in an inert solvent. The carboxylic acids can also be
- 20 activated using dicyclohexylcarbodiimide (DCCI) or O-[(cyano(ethoxycarbonyl)-methylene)amino]-1,1,3,3-tetramethyluronium tetrafluoroborate (TOTU) or other activation reagents customary in peptide chemistry. A number of suitable methods for the preparation of activated carboxylic acid derivatives are indicated with details of

source literature in J. March, Advanced Organic Chemistry, Third Edition, John Wiley & Sons, 1985, p. 350.

The preparation of the compounds of the formula (XII) by reaction of

- 5 2-aminopyrimidine (XI) with a compound of the formula (X) is particularly preferably be carried out in the presence of a base such as triethylamine, L especially preferably being a pentafluorophenoxy group.


The reaction of an activated carboxylic acid derivative of the formula (X) with

- 10 2-aminopyrimidine (XI) is particularly preferably carried out in a manner known per se in an inert, protic or aprotic polar organic solvent such as THF, dimethoxyethane, dioxane, DMF, NMP, but just so water can be used as a solvent with use of a base such as NaOH. Preferably an acid scavenger is added to remove acid formed, for example in the form of excess aminopyrimidine (XI).


15

- In the process for the preparation of a compound (IX-A), the compound of the formula (XII) is then reduced according to a known process (see source literature in March, Advanced Organic Chemistry) to give a compound of the formula (XIII), for example by catalytic hydrogenation over palladium on carbon, the reaction optionally being
20 carried out in a suitable organic solvent, such as ethanol, methanol, acetic acid, THF, diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-butyl ether, dioxane, EA or in a mixture of two or more of these solvents, preferably in ethanol or methanol, for example at temperatures from 0 to 100°C and at hydrogen pressures from 1 to 10 bar.

25




The compound of the formula (XIII) is then deprotected to give the compound of the formula (IX-A) (Greene, Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1999).



Advantageously, when using the benzyloxycarbonyl protective group the hydrogenation of the compound of the formula (XII) and the removal of the protective group to give the compound of the formula (IX-A) can be carried out simultaneously.

Alternatively, a compound (XIII) is obtained by reacting a compound of the formula (X) with 2-amino-1,4,5,6-tetrahydropyrimidine (XIV), where PG and L are as defined above. Bases and solvents which may optionally be added are those mentioned for

the reaction of the compounds (X) and (XI). PG is preferably tert-butoxycarbonyl or benzyloxycarbonyl, L is preferably a pentafluorophenoxy group. The base added can be, for example, excess 2-amino-1,4,5,6-tetrahydropyrimidine (XIV) or triethylamine or diisopropylethylamine.



Depending on the manner of carrying out the process for the preparation and the work-up method, the compounds of the formulae (I-A), (I-B), (IV), (VI), (VII), (VIII), (IX-A), (IX-B), (XI), (XII), (XIII) and (XIV) can also be obtained as salts and/or
 10 employed as salts, for example as acid addition salts with inorganic acids or organic acids, such as hydrogen chloride, hydrogen bromide, sulfuric acid, acetic acid, p-toluenesulfonic acid etc.

In the processes described, compounds of the formulae (I-A), (I-B), (IV), (VI), (VII)
 15 and (VIII) can be obtained and/or employed as individual stereoisomers or as mixtures of two or more stereoisomers in all ratios, for example as R isomers or S isomers or racemates.

The invention also relates to the compounds of the formulae (VII), (VIII), (IX-A), (XII)
 20 and (XIII), in which the radicals R¹ to R⁵ have the meanings indicated above, in all their stereoisomeric forms and mixtures thereof in all ratios, and their salts.

In the preparation of compounds of the formulae (VII), (VIII), (IV), (XII), (XIII), (IX-A), (IX-B), (I-A) and (I-B), it can moreover generally be necessary in the course of the

synthesis temporarily to block functional groups which in the respective synthesis step could lead to undesired reactions or side reactions, by means of a protective group strategy suited to the synthesis problem, which is known to the person skilled in the art (Greene, Wuts, Protective Groups in Organic Synthesis, John Wiley &

- 5 Sons, 1999). Groups in the compounds can also be converted into one another, e.g. a group R⁵ = alkoxy can be converted into a group R⁵ = hydroxyl by means of an ester cleavage.

List of abbreviations:


10

| | |
|-------|--|
| abs. | absolute |
| Boc | tert-butyloxycarbonyl |
| DCCI | dicyclohexylcarbodiimide |
| DCM | dichloromethane |
| DIPEA | diisopropylethylamine |
| DMF | dimethylformamide |
| DMSO | dimethyl sulfoxide |
| EA | ethyl acetate |
| ES | electrospray ionization |
| L | nucleophilically substitutable leaving group |
| LDA | lithium diisopropylamide |
| NMP | N-methylpyrrolidone |
| PG | protective group for amines |
| sec | secondary |
| TEA | triethylamine |
| tert | tertiary |
| THF | tetrahydrofuran |
| Tos | tosyl |
| TOTU | O-[(cyano(ethoxycarbonyl)methylene)amino]-1,1,3,3-tetramethyluronium tetrafluoroborate |

Examples

1) Piperidine-4-carboxylic acid (1,4,5,6-tetrahydropyrimidin-2-yl)amide

5



1a) 1-tert-Butyl 4-pentafluorophenyl piperidine-1,4-dicarboxylate

100 g (436 mmol) of piperidine-1,4-dicarboxylic acid 1-tert butyl ester were dissolved
10 in 1.3 l of anhydrous THF, 39 ml of anhydrous pyridine were added and 86 ml
(500 mmol) of pentafluorophenyl trifluoroacetate were added dropwise with stirring
and with ice-cooling in the course of 30 minutes, and the mixture was allowed to
stand at room temperature for 3 h. The solvent was then stripped off in vacuo and the
residue was taken up in about 2 l of EA, extracted twice each with 0.5 N HCl,
15 saturated NaHCO₃ solution and saturated NaCl solution, and the organic phase was
dried over Na₂SO₄. After evaporating off the solvent in vacuo, an oil remained which
crystallized after addition of heptane. Yield 151.5 g (88%), colorless crystals. M.p.
87-88°C (heptane).

20 1b) tert-Butyl 4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidine-1-carboxylate

29.2 g (73.9 mmol) of the compound of Example 1a) were dissolved in 200 ml of
anhydrous dioxane, 15 ml of anhydrous triethylamine were added and a solution of
7.4 g (74.6 mmol) of 1,4,5,6-tetrahydropyrimidin-2-ylamine in 100 ml of anhydrous
25 dioxane (dissolved with heating and cooled to room temperature again) were added
at room temperature with stirring in the course of 10 minutes with slight cooling with
ice, and the mixture was then allowed to stand overnight at room temperature. The
solvent was evaporated in vacuo, the residue was taken up in about 200 ml of DCM,
extracted twice each with about 200 ml of saturated citric acid solution, saturated

NaHCO_3 solution and saturated NaCl solution, the organic phase was dried over Na_2SO_4 and the solvent was evaporated in vacuo. An oil remained which crystallized after addition of a EA/heptane mixture (about 1:1). Yield 20.92 g (91%), colorless crystals. M.p. 155-160°C (heptane/EA).

5


1c) Piperidine-4-carboxylic acid (1,4,5,6-tetrahydropyrimidin-2-yl)amide bistrifluoroacetate

42.0 g (135.3 mmol) of the compound of Example 1b) were introduced into 200 ml of 10 95 % trifluoroacetic acid with stirring and the mixture was stirred at 25 to 30°C for 1 h. It was then evaporated in vacuo and the residue was evaporated twice in vacuo with about 100 ml of xylene each time. The semicrystalline residue was stirred with THF and then with diisopropyl ether and in each case filtered off with suction. Yield 32.0 g (54%), colorless crystals. M.p. 205-207°C (decomposition with evolution of gas).

15 MS(ES^+): m/e = 211 (100 %, $\text{M}+\text{H}^+$).

$^1\text{H-NMR}$ (400 MHz, DMSO): 1.73 (m, 2H), 1.85 (m, 2H), 1.95 (dd, 2H), 2.7 (m, 1H), 2.95 (bs, 2H), 3.3 (d, 2H), 3.4 (bs, 2H), 3.35-3.55 (2m, 6H, superimposed with H_2O signal), 8.55 (bs, 1H), 8.8 (bs, 1H), 9.35 (s, 2H), 12.1 (s, 1H) ppm.

20 2) Ethyl (2S)-3-(6-chloropurin-9-yl)-2-(naphthalene-1-sulfonylamino)propionate



2a) Ethyl (2S)-3-(6-chloro-5-nitropyrimidin-4-ylamino)-2-(naphthalene-1-sulfonylamino)propionate

2.96 g (29.3 mmol) of triethylamine were added dropwise at -10°C in the course of 5 minutes to 5.0 g (13.9 mmol) of ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-aminopropionate (EP 1070707 (EP 99114372.8)) and 2.84 g (14.6 mmol) of 4,6-dichloro-5-nitropyrimidine, dissolved in 140 ml of abs. THF. The mixture was stirred at -5°C for 15 minutes and then at room temperature for 12 h. The reaction mixture was taken up in EA and extracted with a saturated aqueous NaCl solution, the organic phase was dried over MgSO₄ and filtered, and the solvent was distilled off in vacuo. For purification, the residue was chromatographed over silica gel (EA/heptane 10:3:7). Yield: 6.38 g.

MS(ES⁺): m/e = 482.2 (50%), 480.2 (100%).

¹H-NMR (200 MHz, CDCl₃): 1.12 (t, 3H), 3.80 (t, 2H), 4.03 (q, 2H), 4.23 (dt, 1H), 5.71 (d, 1H), 7.39-8.61 (m, 9H) ppm.

15 2b) Ethyl (2S)-3-(6-chloro-5-amino-pyrimidin-4-ylamino)-2-(naphthalene-1-sulfonylamino)propionate

12.6 g (66.5 mmol) of SnCl₂ were added to 6.38 g (13.3 mmol) of the compound of Example 2a) in 75 ml of ethanol and the reaction mixture was stirred at 70°C for 30 minutes. It was then poured onto 30 g of ice, and the mixture was treated with 17 g of Na₂CO₃ and with 100 ml of EA and stirred for 15 min. The phases were separated, and the aqueous phase was extracted a further two times with EA. The combined organic phases were dried over MgSO₄, filtered and the solvent was distilled off in vacuo. Yield: 5.2 g.

25 MS(ES⁺): m/e = 452.2 (40%), 450.2 (100%).

2c) Ethyl (2S)-3-(6-chloropurin-9-yl)-2-(naphthalene-1-sulfonylamino)propionate

5.2 g of the compound of Example 2b) were dissolved in 20 ml of N-methylpyrrolidone and 33.8 g of triethyl orthoformate and treated with 1.3 g of


ethanesulfonic acid. The reaction mixture was diluted with EA and extracted twice with saturated K_2SO_4 solution, then with a saturated aqueous NaCl solution. The organic phase was dried over $MgSO_4$ and filtered, and the solvent was distilled off in vacuo. For purification, the residue was chromatographed over silica gel

5 (DCM/CH₃OH/CH₃COOH/H₂O 95:5:0.5:0.5). Yield: 4.89 g.

MS(ES⁺): m/e = 462.2 (20%), 460.2 (40%).

3) Ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-{6-[4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)piperidin-1-yl]purin-9-yl}propionate

10




3.21 g of ethyl (2S)-3-(6-chloropurin-9-yl)-2-(naphthalene-1-sulfonylamino)propionate (Example 2) in 20 ml of abs. DMF were treated with 4.0 g of 7-(piperidin-4-yl)-1,2,3,4-

15 tetrahydro-[1,8]naphthyridine and 3.88 g of diisopropylethylamine, and the mixture was stirred at 70°C for 3 h. The solvent was distilled off in vacuo, the residue was taken up in EA and the mixture was extracted three times with water. The aqueous phases were extracted three times with DCM. The combined organic phases were dried over $MgSO_4$ and filtered, and the solvent was distilled off in vacuo. For

20 purification, the residue was chromatographed over silica gel (DCM/CH₃OH/CH₃COOH/H₂O 95:5:0.5:0.5). Yield: 3.29 g.

MS(ES⁺): m/e = 641.4 (50%), 321.4 (100%).

4) tert-Butyl (2S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionate



4a) tert-Butyl (2S)-3-(6-chloro-5-nitro-4-pyrimidin-4-ylamino)-2-
 5 benzyloxycarbonylaminopropionate
 8.9 g (30.2 mmol) of tert-butyl (2S)-3-amino-2-benzyloxycarbonylaminopropionate
 were dissolved in 300 ml of abs. THF and treated at -10°C with 6.15 g (31.8 mmol) of
 4,6-dichloro-5-nitropyrimidine and 4.4 ml (31.8 mmol) of triethylamine. The cooling
 10 bath was removed and the reaction mixture reached room temperature after 30
 minutes. The mixture was stirred for a further 12 h. The solvent was distilled off in
 vacuo, the residue was partitioned between EA and a saturated aqueous NaCl
 solution, the organic phase was dried over MgSO₄ and filtered, and the solvent was
 distilled off in vacuo. For purification, the residue was chromatographed over silica
 15 gel (EA/heptane 3:7). Yield: 11.27 g.

¹H-NMR (200 MHz, CDCl₃): 1.48 (s, 9H), 3.81-4.00 (m, 1H), 4.02-4.58 (m, 1H),
 4.42-4.58 (m, 1H), 5.11 (s, 2H), 5.56 (d, broad, 1H), 7.36 (s, 5H), 7.80 (s, broad, 1H),
 8.32 (s, 1H) ppm.

20 4b) tert-Butyl (2S)-3-(6-chloro-5-aminopyrimidin-4-ylamino)-2-
 benzyloxycarbonylaminopropionate

9.0 g of the compound of Example 4a) in 40 ml of ethanol were treated with 18.96 g of SnCl₂ and the reaction mixture was stirred at 70°C for 30 minutes under nitrogen. The reaction solution was poured onto 40 g of ice, 150 ml of EA and 25 g of Na₂CO₃ were added and the mixture was stirred for 15 min. It was then filtered, the aqueous 5 phase was extracted a further two times with EA, the combined organic phases were washed with a saturated NaCl solution, dried over MgSO₄ and filtered, and the solvent was distilled off in vacuo. Yield: 6.73 g.

MS(ES⁺): m/e = 424.3 (35%), 422.3 (100%).


10 4c) tert-Butyl (2S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionate

8.46 g of the compound of Example 4b) were dissolved in 50 ml of triethyl orthoformate and treated with 279 mg of ethanesulfonic acid. The mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with 750 ml of EA and 15 extracted three times with NaHCO₃ solution and washed twice with a saturated aqueous NaCl solution. The organic phase was dried over MgSO₄ and filtered, and the solvent was distilled off in vacuo. For purification, the residue was chromatographed over silica gel (EA/heptane 1:1). Yield: 6.64 g.

MS(ES⁺): m/e = 434.3 (35%), 432.3 (100%).

20

5) tert-Butyl (2S)-2-benzyloxycarbonylamino-3-[6-[4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl]purin-9-yl]propionate




65 g (150.5 mmol) of tert-butyl (2S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionate (Example 4) were dissolved in 350 ml of anhydrous THF, 100 ml of
5 anhydrous triethylamine were added and then 74 g (168.8 mmol) of piperidine-4-
carboxylic acid (1,4,5,6-tetrahydropyrimidin-2-yl)amide bistrifluoroacetate (Example
1) were introduced with stirring at room temperature and the mixture was stirred at
50°C for approximately 8 h. After evaporation of the solvent in vacuo, a brown oil
remained which was purified by chromatography over silica gel (eluent: EA, then
10 EA/methanol 10:1). Yield: 86.5 g (95%) of slightly yellowish foam.

MS(ES⁺): m/e = 606 (85 %, M+H⁺), 304 (100%).

¹H-NMR (400 MHz, DMSO): 1.3 (s, 9H), 1.55 (q, 1H), 1.85 (m, 1H), 1.95 (m, 1H), 2.8 (m, 1H), 3.2 (m, 1H), 3.35 (m, 2H), 4.45 (m, 1H), 4.5-4.6 (2m, 2H), 5.0 (s, 2H), 5.25-5.45 (bs, 2H), 7.25-7.4 (sh, 5H), 7.9 (d, 1H), 8.1 (s, 1H), 8.25 (s, 1H), 9.0 (s, 2H)
15 ppm.

Patent Claims

1) A process for the preparation of a compound of the formula (IV)



5

(IV)

wherein

- R¹, R², R³, R⁴ independently of one another are hydrogen, fluorine, chlorine, CN,
10 (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶R^{6'}N-R⁷, R⁶C(O)R⁷,
R⁶S(O)₂N(R⁹)R⁷, R⁶OC(O)N(R⁹)R⁷, R⁶C(O)N(R⁵)R⁷, R⁶N(R⁹)C(O)N(R⁹)R⁷,
R⁶N(R⁹)S(O)₂N(R⁹)R⁷, R⁶S(O)₂R⁷, R⁶SC(O)N(R⁹)R⁷, R⁶N(R⁹)C(O)R⁷,
R⁶N(R⁹)S(O)₂R⁷, R⁶N(R⁹)R⁷ or a 3-membered to 7-membered, saturated or
15 unsaturated ring which can contain one or two heteroatoms from the group consisting
of nitrogen, sulfur and oxygen and which can be unsubstituted or mono- or
disubstituted by =O, =S and R⁸,
where alkyl, cycloalkyl and aryl radicals can be mono- or polysubstituted by fluorine,
chlorine, bromine, CF₃, CN, R⁶N(R⁹)R⁷, R⁶R^{6'}NR⁷, R⁶C(O)R⁷, R⁶N(R⁹)C(O)R⁷,
20 R⁶N(R⁹)S(O)₂R⁷, R⁶, R⁶-O-R⁷;

R⁵ is hydroxyl, (C₁-C₈)-alkoxy, (C₅-C₁₄)-aryl-(C₁-C₈)-alkoxy-, (C₁-C₈)-alkylcarbonyloxy-(C₁-C₄)-alkoxy-, (C₃-C₁₄)-cycloalkoxy or (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkoxy-;

5

R⁶, R^{6'} independently of one another are (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- or a 3-membered to 7-membered, saturated or unsaturated ring which can contain one or two heteroatoms from the group consisting of nitrogen, sulfur and oxygen, and is

- 10 unsubstituted or mono- or disubstituted by =O, =S and R⁸, where aryl, cycloalkyl and alkyl radicals can be substituted once, twice or three times by fluorine, chlorine, bromine, cyano, CF₃, nitro, carboxyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₅-C₁₄)-aryl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl, (C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkylaminocarbonyl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-,
15 (C₅-C₁₄)-aryl-(C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkanoylamino, (C₅-C₁₄)-arylsulfonylamino, (C₁-C₆)-alkylsulfonylamino, (C₁-C₆)-alkylamino, di-((C₁-C₆)-alkyl)amino, (C₁-C₆)-alkylsulfonyl, (C₁-C₆)-alkylaminosulfonyl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkylaminosulfonyl or (C₅-C₁₄)-aryl-(C₁-C₆)-alkylsulfonyl;
20 R⁷ independently of one another is (C₁-C₄)-alkanediyil or a direct bond;

- R⁸ is (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, cyano, CF₃, nitro, carboxyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl,
25 (C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkylaminocarbonyl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₆)-alkylcarbonyl, (C₁-C₆)-alkanoylamino, (C₅-C₁₄)-arylsulfonylamino, (C₁-C₆)-alkylsulfonylamino, (C₁-C₆)-alkylamino, di-(C₁-C₆)-

alkylamino, (C₁-C₆)-alkylsulfonyl, (C₁-C₆)-alkylaminosulfonyl, (C₆-C₁₄)-aryl-(C₁-C₆)-alkylaminosulfonyl or (C₅-C₁₄)-aryl-(C₁-C₆)-alkylsulfonyl; and


R⁹ is hydrogen or (C₁-C₄)-alkyl;

5


in all its stereoisomeric forms and mixtures thereof in all ratios, and its salts,

which comprises

- 10 reacting the 5-nitropyrimidine of the formula (V) with a primary amine of the formula (VI) to give a compound of the formula (VII),



- 15 reducing the compound of the formula (VII) to a compound of the formula (VIII)



and cyclizing the compound of the formula (VIII) to a compound of the formula (IV) by means of a C₁ unit.

5


2) The process as claimed in claim 1, wherein

- R¹, R², R³, R⁴ independently of one another are hydrogen, (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, R⁶R^{6'}N-R⁷, R⁶S(O)₂N(R⁹)R⁷, R⁶N(R⁹)S(O)₂N(R⁹)R⁷,
 - 10 R⁶OC(O)N(R⁹)R⁷, R⁶C(O)N(R⁹)R⁷, R⁶N(R⁹)R⁷ or a 3-membered to 7-membered, saturated or unsaturated ring which can contain one or two heteroatoms from the group consisting of nitrogen, sulfur and oxygen and which can optionally be mono- or disubstituted by =O, =S and R⁸,
 - 15 where alkyl, cycloalkyl and aryl radicals can be mono- or polysubstituted by fluorine, chlorine, bromine, CF₃, CN and R⁶-O-R⁷;
- R⁵ is hydroxyl or (C₁-C₄)-alkoxy;

- R⁶, R^{6'} independently of one another are (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- or a 3-membered to 7-membered, saturated or unsaturated ring, which can contain one or two heteroatoms from the group consisting of nitrogen, sulfur and oxygen and which
- 5 can optionally be mono- or disubstituted by =O, =S and R⁸, where aryl, cycloalkyl and alkyl radicals can be mono- to trisubstituted by fluorine, chlorine, bromine, cyano, CF₃, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₅-C₁₄)-aryl, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl, (C₁-C₆)-alkylcarbonyl;
- 10 R⁷ independently of one another is (C₁-C₄)-alkylene or a direct bond; R⁸ is (C₁-C₁₄)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, CF₃, (C₁-C₆)-alkoxy or (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-; and
- 15 R⁹ is hydrogen or (C₁-C₄)-alkyl.
- 3) The process as claimed in claims 1 to 2, wherein
- 20 R¹, R², R³, R⁴ independently of one another are hydrogen, R⁶S(O)₂N(R⁹)R⁷ or R⁶OC(O)N(R⁹)R⁷;
- R⁵ is (C₁-C₄)-alkoxy;
- 25 R⁶ is (C₅-C₁₄)-aryl or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl;
- R⁷ is a direct bond; and

R⁹ is hydrogen.


4) A compound of the formula (VII),



5

wherein R¹ to R⁵ are as defined in claims 1 to 3, in all its stereoisomeric forms and mixtures thereof in all ratios, and its salts.


10 5) A compound of the formula (VIII),



wherein R¹ to R⁵ are as defined in claims 1 to 3, in all its stereoisomeric forms and mixtures thereof in all ratios, and its salts.

6) A process for the preparation of the compound of the formula (IX-A)


5



and its salts,


10 which comprises

reacting a compound of the formula (X) with 2-aminopyrimidine of the formula (XI) to give a compound of the formula (XII),




where PG is an amino protective group and L is a nucleophilically substitutable leaving group,

5 and reducing the compound of the formula (XII) to the compound of the formula (XIII),



(XIII)

or reacting a compound of the formula (X) with 2-amino-1,4,5,6-tetrahydropyrimidine
10 of the formula (XIV) to give a compound of the formula (XIII),




(XIV)


and deprotecting the compound of the formula (XIII) to give the compound of the
15 formula (IX-A).

7) The process as claimed in claim 6, wherein PG is tert-butoxycarbonyl or
benzyloxycarbonyl.


- 8) The process as claimed in claims 6 to 7, wherein L is pentafluorophenoxy.
- 9) A compound of the formula (XII), wherein PG is an amino protective group, and its
5 salts.



- 10) A compound of the formula (XIII), wherein PG is an amino protective group, and
10 its salts.




- 11) The compound of the formula (IX-A) and its salts.



(IX-A)

12) A process for the preparation of a compound of the formula (I-A),

5




wherein the radicals R¹ to R⁵ are as defined in claims 1 to 3, in all its stereoisomeric forms and mixtures thereof in all ratios, and its salts, which comprises reacting a compound of the formula (IV) with a compound of the formula (IX-A).

- 5 13) A process for the preparation of a compound of the formula (I-A), wherein the radicals R¹ to R⁵ are as defined in claims 1 to 3, in all its stereoisomeric forms and mixtures thereof in all ratios, and its salts,


which comprises

10

reacting the compound of the formula (V) with a compound of the formula (VI),




- 15 reducing the compound of the formula (VII) obtained to the compound of the formula (VIII),



(VIII)

reacting the compound of the formula (VIII) with a C₁ unit to give the compound of the formula (IV), and reacting the compound of the formula (IV) with the compound of
5 the formula (IX-A) to give the compound of the formula (I-A).




14) A process for the preparation of a compound of the formula (I-B), wherein the radicals R¹ to R⁵ are as defined in claims 1 to 3, in all its stereoisomeric forms and mixtures thereof in all ratios, and its salts,

5


which comprises

reacting the compound of the formula (V) with a compound of the formula (VI),




10

reducing the compound of the formula (VII) obtained to the compound of the formula (VIII),




(VIII)


reacting the compound of the formula (VIII) with a C₁ unit to give the compound of the formula (IV), and reacting the compound of the formula (IV) with the compound of
5 the formula (IX-B) to give the compound of the formula (I-B).



- 15) The use of a compound of the formula (IV) for the preparation of a pharmaceutical active compound, which comprises reacting a compound of the formula (IV) with the compound of the formula (IX-A) to give a compound of the
 5 formula (I-A), wherein the radicals R¹ to R⁵ are as defined in claims 1 to 3.



- 16.) The use of a compound of the formula (IV) for the preparation of a
 10 pharmaceutical active compound, which comprises reacting a compound of the formula (IV) with the compound of the formula (IX-B) to give a compound of the formula (I-B), wherein the radicals R¹ to R⁵ are as defined in claims 1 to 3,
 with the exception of compounds of the formula (I-B) in which R¹ and R² are
 15 hydrogen, one of the radicals R³ and R⁴ is benzyl-O-C(O)-NH- and the other is
 hydrogen, and R⁵ is hydroxyl or tert-butoxy.



INTERNATIONAL SEARCH REPORT

| | |
|---------|-------------------|
| Inte | al Application No |
| PC., .. | 01/09985 |

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D473/40 C07D473/34 C07D239/42 C07D239/48 C07D401/12
C07D519/00 // (C07D519/00, 473:00, 471:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | EP 0 853 084 A (HOECHST AG ;GENENTECH INC (US)) 15 July 1998 (1998-07-15) cited in the application claims --- | 1-16 |
| A | EP 0 434 450 A (WELLCOME FOUND) 26 June 1991 (1991-06-26) claims --- | 1-16 |
| P,A | EP 1 065 207 A (AVENTIS PHARMA GMBH ;GENENTECH INC (US)) 3 January 2001 -(2001-01-03) cited in the application claims --- | 1-16 |
| | -/- | |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

| | |
|--|--|
| Date of the actual completion of the international search | Date of mailing of the international search report |
| 4 January 2002 | 14/01/2002 |
| Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | Authorized officer Chouly, J |

INTERNATIONAL SEARCH REPORT

Inte al Application No
PC., L? 01/09985

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| P,A | EP 1 065 208 A (AVENTIS PHARMA GMBH ;GENENTECH INC (US)) 3 January 2001 (2001-01-03) cited in the application claims ----- | 1-16 |

INTERNATIONAL SEARCH REPORT

| | |
|---------|-------------------|
| Intel | al Application No |
| PC., L. | 01/09985 |

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|--|---|------------------|--|--|--|--|
| EP 0853084 | A | 15-07-1998 | DE AU AU BR CA CN CZ EP HU JP NO PL TR US | 19653646 A1 728865 B2 4846697 A 9706387 A 2225366 A1 1193623 A 9704114 A3 0853084 A2 9702507 A2 10182645 A 975977 A 323969 A1 9701647 A2 6218387 B1 | | 25-06-1998 18-01-2001 25-06-1998 14-03-2000 20-06-1998 23-09-1998 15-07-1998 15-07-1998 28-05-1999 07-07-1998 22-06-1998 22-06-1998 21-07-1998 17-04-2001 |
| EP 0434450 | A | 26-06-1991 | AP AT AU AU CA CN CZ CZ DE DE DK EP EP EP ES FI FI FI GR HK HU HU IE IL JP JP KR LU MX NZ PL PT SG SK SK RU RU US ZA | 196 A 181917 T 633672 B2 6841990 A 2033044 A1 1054981 A ,B 9202470 A3 9006583 A3 69033197 D1 69033197 T2 434450 T3 0434450 A2 0921121 A1 0921114 A1 2133138 T3 906367 A 970666 A 20001175 A 3031100 T3 1009600 A1 219454 B 220067 B 904652 A1 96748 A 11343292 A 11158160 A 192994 B1 90426 A9 9203215 A1 236593 A 167097 B1 96321 A ,B 49685 A1 247092 A3 658390 A3 2068849 C1 2091386 C1 5206435 A 9010365 A | | 30-06-1992 15-07-1999 04-02-1993 27-06-1991 23-06-1991 02-10-1991 15-04-1998 12-11-1997 12-08-1999 28-10-1999 31-01-2000 26-06-1991 09-06-1999 09-06-1999 01-09-1999 23-06-1991 17-02-1997 16-05-2000 31-12-1999 05-05-2000 28-04-2001 28-10-2001 17-07-1991 31-07-1995 14-12-1999 15-06-1999 15-06-1999 06-10-1999 01-07-1992 26-01-1994 31-07-1995 30-09-1991 15-06-1998 11-06-1999 08-10-1999 10-11-1996 27-09-1997 27-04-1993 26-08-1992 |
| EP 1065207 | A | 03-01-2001 | EP AU WO | 1065207 A1 5978700 A 0102398 A1 | | 03-01-2001 22-01-2001 11-01-2001 |

INTERNATIONAL SEARCH REPORT

| |
|------------------------------|
| International Application No |
| PC ..., 01/09985 |

| Patent document cited in search report | Publication date | | Patent family member(s) | | Publication date |
|--|------------------|----------------|---------------------------------------|--|--|
| EP 1065208 A | 03-01-2001 | EP AU WO | 1065208 A1 5534900 A 0102399 A1 | | 03-01-2001 22-01-2001 11-01-2001 |